<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>   <meta charset="utf-8" />
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 10">
<meta name=Originator content="Microsoft Word 10">
<link rel=File-List href="onkoloji_dosyalar/filelist.xml">
<link rel=Edit-Time-Data href="onkoloji_dosyalar/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>Nï¿½RO-ONKOLOJ&#304;</title>
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421319 -2147483648 8 0 66047 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h2
	{mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	mso-outline-level:2;
	font-size:18.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
p
	{mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.dzeltme, li.dzeltme, div.dzeltme
	{mso-style-name:dzeltme;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
span.msons
	{mso-style-name:mso\0131ns;
	text-decoration:underline;
	text-underline:single;}
span.msodel0
	{mso-style-name:msodel;
	color:red;
	text-decoration:line-through;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:70.85pt 70.85pt 70.85pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 @list l0
	{mso-list-id:52310603;
	mso-list-type:hybrid;
	mso-list-template-ids:1844508232 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1
	{mso-list-id:64183340;
	mso-list-template-ids:-2017965868;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l2
	{mso-list-id:64960796;
	mso-list-template-ids:1387163614;}
@list l2:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l3
	{mso-list-id:259025450;
	mso-list-template-ids:1438812400;}
@list l3:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l4
	{mso-list-id:626276504;
	mso-list-template-ids:-1137162906;}
@list l4:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l5
	{mso-list-id:704603199;
	mso-list-type:hybrid;
	mso-list-template-ids:139478852 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l5:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l5:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6
	{mso-list-id:821579602;
	mso-list-template-ids:2014490080;}
@list l6:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l7
	{mso-list-id:884174953;
	mso-list-template-ids:-1872969842;}
@list l7:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l8
	{mso-list-id:960187075;
	mso-list-template-ids:-1054825630;}
@list l8:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l9
	{mso-list-id:1184976250;
	mso-list-type:hybrid;
	mso-list-template-ids:406593606 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l9:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l9:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l10
	{mso-list-id:1219434258;
	mso-list-template-ids:1782080580;}
@list l10:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l11
	{mso-list-id:1404639509;
	mso-list-type:hybrid;
	mso-list-template-ids:-641023698 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l11:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l11:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12
	{mso-list-id:1425418758;
	mso-list-type:hybrid;
	mso-list-template-ids:-529001096 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l12:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l12:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l13
	{mso-list-id:1529374179;
	mso-list-template-ids:-242698810;}
@list l13:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l14
	{mso-list-id:1690183908;
	mso-list-template-ids:-784795596;}
@list l14:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l15
	{mso-list-id:1789540707;
	mso-list-template-ids:-1674248846;}
@list l15:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l16
	{mso-list-id:1789548008;
	mso-list-type:hybrid;
	mso-list-template-ids:1787471864 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l16:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l16:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17
	{mso-list-id:2051222365;
	mso-list-type:hybrid;
	mso-list-template-ids:-1433254462 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l17:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l17:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Normal Tablo";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
table.MsoTableGrid
	{mso-style-name:"Tablo K\0131lavuzu";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	border:solid windowtext 1.0pt;
	mso-border-alt:solid windowtext .5pt;
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-border-insideh:.5pt solid windowtext;
	mso-border-insidev:.5pt solid windowtext;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
</style>
<![endif]-->
</head>

<body lang=EN-US link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nï¿½RO-ONKOLOJ&#304;</span></h2>

<h2><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Erdem Tï¿½zï¿½n, Gï¿½l&#351;en Akman Demir, Jale Yaz&#305;c&#305;</span></h2>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Son
gï¿½ncelle&#351;tirme tarihi: 1. 7. 2009</span></b><a name=G&#304;R&#304;&#350;></a></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Resim iï¿½ermeyen bu bï¿½lï¿½mde yer alan tï¿½mï¿½ral olu&#351;umlar&#305;n
birï¿½o&#287;una ait makroskopik ve histopatolojik &#351;ekiller <span
style='color:#0070C0'><a href="../noropatoloji/noropatoloji.htm">Sinir Sistemi
Semiyolojisi/Nï¿½rolojide Laboratuvar &#304;ncelemeleri/<b>Nï¿½ropatoloji</b></a></span>
bï¿½lï¿½mï¿½nde bulunabilir. </span></p>

</div>

<p><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>G&#304;R&#304;&#350;</span></b><span lang=TR style='font-size:14.0pt;
font-family:Tahoma;mso-ansi-language:TR'> </span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Sinir
sisteminin tï¿½mï¿½rlerle ï¿½e&#351;itli ili&#351;kilerini inceleyen bir bilim
dal&#305; olan nï¿½ro-onkolojinin kapsam&#305; iï¿½inde primer sinir sistemi
tï¿½mï¿½rlerinin yan&#305; s&#305;ra sistemik kanserlerin nï¿½rolojik etkileri
(metastaz, lokal yay&#305;l&#305;m, radyoterapi veya kemoterapi yan etkileri,
tï¿½mï¿½rï¿½n hematolojik-metabolik uzak etkileri ve paraneoplastik sendromlar) yer
al&#305;r. </span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p><a name="PR&#304;MER_BEY&#304;N"></a><b><span lang=TR style='font-size:14.0pt;
font-family:Tahoma;mso-ansi-language:TR'>PR&#304;MER BEY&#304;N Tï¿½Mï¿½RLER&#304;</span></b><span
lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Primer veya
sekonder beyin tï¿½mï¿½rlerinde tï¿½mï¿½rï¿½n davran&#305;&#351; ï¿½zellikleri birbirinden
farkl&#305;l&#305;k gï¿½sterse de genelde kar&#351;&#305;la&#351;&#305;lan klinik
tablo kafa iï¿½i bas&#305;nï¿½ art&#305;&#351;&#305; sendromudur. Ayr&#305;ca
tï¿½mï¿½rï¿½n lokalizasyonuna gï¿½re de&#287;i&#351;en ï¿½e&#351;itli nï¿½rolojik belirti
ve bulgular ve/veya epileptik nï¿½betler gï¿½rï¿½lebilir. Bu bï¿½lï¿½mde tï¿½mï¿½rlerin
yaratt&#305;&#287;&#305; klinik tablolar&#305;n ï¿½zerinde durulmayacakt&#305;r;
tï¿½mï¿½re ba&#287;l&#305; ortaya ï¿½&#305;kan metabolik sorunlar&#305;n sinir
sistemi ï¿½zerindeki etkileri de k&#305;saca s&#305;ralanacakt&#305;r; dileyen
okur bu kitapta yer alan ve bu konular&#305;n anlat&#305;ld&#305;&#287;&#305;
di&#287;er bï¿½lï¿½mlere ba&#351;vurabilir ( Bak&#305;n&#305;z: &nbsp;<span
style='color:#4F81BD'><a href="../kibas/kibas.htm">Kafa iï¿½i bas&#305;nc&#305;
de&#287;i&#351;iklikleri</a></span>, <span style='color:#4F81BD'><a
href="../epilepsi/Epilepsi.htm">Epilepsi</a></span>, <span style='color:#4F81BD'><a
href="../beslenme/beslenme.htm">Sinir sisteminin nutrisyonel
hastal&#305;klar&#305;</a></span>). </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidemiyoloji</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kansere
ba&#287;l&#305; ï¿½lï¿½mler aras&#305;nda primer beyin tï¿½mï¿½rleri gï¿½rece kï¿½ï¿½ï¿½k bir
bï¿½lï¿½mï¿½ olu&#351;turur (y&#305;lda yakla&#351;&#305;k 100 000ï¿½de 3000). Ancak bu
rakam&#305;n yakla&#351;&#305;k 10 kat&#305; kadar bir grupta da di&#287;er
kanserlerin komplikasyonlar&#305; sonucu MSSï¿½nin tutulmas&#305; ile ï¿½lï¿½m ortaya
ï¿½&#305;kar. Amerika Birle&#351;ik Devletleriï¿½nde ortalama 300 milyonluk bir
nï¿½fusta her y&#305;l yakla&#351;&#305;k 24 000 yeni primer beyin tï¿½mï¿½rï¿½
tan&#305;s&#305; konmaktad&#305;r. Tï¿½rkiyeï¿½de ise kesin bir rakam verilememekle
birlikte oran&#305;n benzer oldu&#287;u san&#305;lmaktad&#305;r.
Eri&#351;kinlere k&#305;yasla ï¿½ocuklarda primer beyin tï¿½mï¿½rlerinin gï¿½rï¿½lme
s&#305;kl&#305;&#287;&#305; yï¿½ksek olup, lï¿½seminin ard&#305;ndan ikinci
s&#305;ray&#305; al&#305;r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Primer beyin
tï¿½mï¿½rleri iï¿½inde en s&#305;k gï¿½rï¿½len gliomlard&#305;r (% 50), bunu meningiomlar
(% 15) izler (<b>Tablo 1</b>). ï¿½ocuklarda ise da&#287;&#305;l&#305;m daha
farkl&#305;d&#305;r (<b>Tablo 2</b>). Ayr&#305;ca eri&#351;kinlerde primer
beyin tï¿½mï¿½rleri s&#305;kl&#305;kla (% 70) supratentoriyal yerle&#351;im
gï¿½sterirken, ï¿½ocuklarda infratentoriyal yerle&#351;im % 70
oran&#305;ndad&#305;r. &#350;iddetli ba&#351;a&#287;r&#305;s&#305; anamneziyle
getirilen bir ï¿½ocukta, tan&#305; olas&#305;l&#305;klar&#305; iï¿½inde arka ï¿½ukur
tï¿½mï¿½rï¿½ ilk s&#305;rada olmal&#305;d&#305;r<i>.</i> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>S&#305;n&#305;flama</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Primer beyin
tï¿½mï¿½rleri ile ilgili Dï¿½nya Sa&#287;l&#305;k ï¿½rgï¿½tï¿½nï¿½n (WHO) son
s&#305;n&#305;flamas&#305;nda, gliomlar&#305;n en s&#305;k tipi olan diffï¿½z
astrositik tï¿½mï¿½rler 4 gruba ayr&#305;lm&#305;&#351;t&#305;r: <br>
&nbsp; </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='mso-list:l17 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>grad 1 astrositom
     (ï¿½ok nadirdir ve hamartomdan ay&#305;rdedilmesi gï¿½ï¿½tï¿½r), </span><span
     lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></li>
 <li class=MsoNormal style='mso-list:l17 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>grad 2 astrositom,
     </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
 <li class=MsoNormal style='mso-list:l17 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>grad 3 anaplastik
     astrositom </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
 <li class=MsoNormal style='mso-list:l17 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>grad 4
     glioblastoma multiforme. <br>
     &nbsp; </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
</ul>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Burada gerek
atipi, damarlanma, mitoz ï¿½zellikleri ile karakterize bï¿½yï¿½me potansiyeli,
gerekse prognoz bak&#305;m&#305;ndan giderek kï¿½tï¿½le&#351;me sï¿½z konusudur. Bu
s&#305;n&#305;flaman&#305;n d&#305;&#351;&#305;nda tutulan gliomlar da
vard&#305;r. ï¿½zellikle ï¿½ocuklarda ve genï¿½lerde gï¿½rï¿½len pilositik astrositom
(WHO grad 1ï¿½e denk gelir) ve ayr&#305;ca dev hï¿½creli astrositom farkl&#305;
bï¿½yï¿½me ve s&#305;n&#305;rlanma ï¿½zellikleri ve farkl&#305; prognozlar&#305; nedeniyle
genellikle ayr&#305; ele al&#305;n&#305;r. Ependimomlar da hï¿½cre tipine gï¿½re 4
alt gruba ayr&#305;l&#305;r. Benzer &#351;ekilde oligodendroglial tï¿½mï¿½rler de
ayr&#305; bir kategoride ele al&#305;n&#305;r (WHO grad 2: oligodendrogliom,
WHO grad 3: anaplastik oligodendrogliom ve mikst gliomlar). Meningiomlar da
hï¿½cre yap&#305;s&#305; aï¿½&#305;s&#305;ndan alt gruplara ayr&#305;l&#305;r:
meningotelyal (sinsisyal) tip, anaplastik (habis) tip ve atipik gruplar. Pineal
tï¿½mï¿½rler pineasitom, pinealoblastom ve embriyonal formlar olarak
s&#305;n&#305;flan&#305;r. Medulloblastomlar ise nï¿½roektodermal kï¿½kenli oldu&#287;u
dï¿½&#351;ï¿½nï¿½len di&#287;er tï¿½mï¿½rlerle (nï¿½roblastom, retinoblastom ve
ependimoblastom) birlikte tekrar s&#305;n&#305;flanm&#305;&#351;t&#305;r.
Kranyal ve periferik sinirlerin tï¿½mï¿½rleri ise 3 grupta ele al&#305;n&#305;r:
Schwannom, nï¿½rofibrom ve nï¿½rofibrosarkom. Bï¿½tï¿½n bu say&#305;lanlar&#305;n
d&#305;&#351;&#305;nda ayr&#305; ele al&#305;nan pek ï¿½ok tï¿½mï¿½r daha
vard&#305;r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>Tablo 1. Eri&#351;kinlerde Primer MSS Tï¿½mï¿½rlerinin
Da&#287;&#305;l&#305;m&#305;</span></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> (</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Kaynak 2 ve 25ï¿½ten
de&#287;i&#351;tirilerek adapte edildi)</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;background:#FFFFCC;mso-padding-alt:
 0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:black;
  mso-ansi-language:TR'>Tï¿½mï¿½r Tipi</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:black;
  mso-ansi-language:TR'>S&#305;kl&#305;k</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:black;
  mso-ansi-language:TR'>Ya&#351;</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:black;
  mso-ansi-language:TR'>5 y&#305;ll&#305;k sa&#287;kal&#305;m</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;color:#000099;
  mso-ansi-language:TR'>Gliomlar&nbsp;</span></b></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 50</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Glioblastoma multiforme</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 20&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>62&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 6</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Astrositom&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 10&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>50-55</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 20-30</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Ependimom&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 6</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>25</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 50</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Oligodendrositom&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 5</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;43</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 61</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Medulloblastom</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 4</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>S&#305;n&#305;flanamayan gliom&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 5</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;color:black;
  mso-ansi-language:TR'>Meningiom</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 15</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;61</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 91</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Hipofiz adenomu</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 7</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Nï¿½rinom (Schwannoma)</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><br>
  &nbsp;% 7&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>52 %&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>96</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Kranyofaringiom, teratom,dermoid, epidermoid t</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 4</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Anjiomlar</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>% 4</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Sarkomlar</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 4</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Di&#287;er (pinealom, kordom, vs)</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 3</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Lenfoma</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;% 1.5- 15*</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p style='margin-bottom:12.0pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>*Kaynak al&#305;nan yay&#305;n&#305;n y&#305;l&#305; ile
de&#287;i&#351;mektedir. Yak&#305;n tarihli yay&#305;nlarda
s&#305;kl&#305;&#287;&#305;n&#305;n ï¿½ok artt&#305;&#287;&#305; dikkati
ï¿½ekmektedir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>Tablo 2. ï¿½ocuklarda MSS Tï¿½mï¿½rlerinin Da&#287;&#305;l&#305;m&#305; </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(Kaynak
2, 23 ve 25ï¿½ten adapte edildi)</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellpadding=0 width="84%"
 style='width:84.56%;mso-cellspacing:1.5pt;margin-left:-4.2pt;background:#FFFFCC;
 mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width="88%" style='width:88.34%;background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Tï¿½mï¿½r tipi&nbsp;</span></b></p>
  </td>
  <td width="10%" style='width:10.52%;background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>S&#305;kl&#305;&#287;&#305;</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width="88%" style='width:88.34%;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Gliomlar </span></p>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l0 level1 lfo6;tab-stops:list 36.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
       TR'>Astrositom</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
       TR'> </span></li>
   <li class=MsoNormal style='mso-list:l0 level1 lfo6;tab-stops:list 36.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
       TR'>Medulloblastom</span><span lang=TR style='font-family:Tahoma;
       mso-ansi-language:TR'> </span></li>
   <li class=MsoNormal style='mso-list:l0 level1 lfo6;tab-stops:list 36.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
       TR'>Ependimom</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
       TR'> </span></li>
  </ul>
  </td>
  <td width="10%" style='width:10.52%;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;&gt;% 80&nbsp; <br>
  &nbsp;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'> % 55&nbsp;</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp; % 20&nbsp;</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp; % 8</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width="88%" style='width:88.34%;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Kranyofaringiom&nbsp;</span></p>
  </td>
  <td width="10%" style='width:10.52%;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp; % 5</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;mso-yfti-lastrow:yes'>
  <td width="88%" style='width:88.34%;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Di&#287;er (germ hï¿½c. t., pineal t., koroid pl t.,ilkel nï¿½roektodermal
  t., vb.)&nbsp;</span></p>
  </td>
  <td width="10%" style='width:10.52%;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp; % 12</span></p>
  </td>
 </tr>
</table>

</div>

<p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Patogenez</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> </span></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Primer beyin tï¿½mï¿½rlerinin patogenezi tart&#305;&#351;&#305;l&#305;rken
ba&#351;l&#305;ca iki ana hipotez ï¿½zerinde durulur. Bunlardan 1800ï¿½lï¿½
y&#305;llardan bu yana ï¿½ne sï¿½rï¿½len ilki; beyin tï¿½mï¿½rlerinin embriyonel
kal&#305;nt&#305;lardan ve kï¿½k hï¿½crelerin diferansiyasyon s&#305;ras&#305;nda
blastik de&#287;i&#351;im gï¿½stermesinden kaynakland&#305;&#287;&#305;n&#305;
savunan hipotezdir. Bugï¿½n daha fazla kabul gï¿½ren di&#287;er hipotez ise
olgunla&#351;m&#305;&#351; eri&#351;kin hï¿½crelerin ard&#305;l mutasyonlar
sonucunda kontrolsï¿½z proliferasyonu ve dediferansiyasyonu hipotezidir. Son
y&#305;llarda bu ikinci hipotezi do&#287;rulayan pek ï¿½ok onkogen ve tï¿½mï¿½r
bask&#305;lay&#305;c&#305; gen tan&#305;mlanm&#305;&#351;t&#305;r. Tï¿½mï¿½r
bask&#305;lay&#305;c&#305; genlerden en ï¿½nemlisi 17. kromozomdaki P53 genidir.
P53 geni hï¿½cre siklusunun dï¿½zenlenmesinde, DNA hasar&#305;na cevapta ve
programlanm&#305;&#351; hï¿½cre ï¿½lï¿½mï¿½nde (apoptoz) ï¿½nemli rol oynar. Normal
i&#351;lev gï¿½steren P53 geninin glioblastom hï¿½cre serilerini
bask&#305;lad&#305;&#287;&#305;, mutant P53 geninin ise transformasyon gï¿½steren
astrositlerin ï¿½lï¿½msï¿½zle&#351;mesinde rol oynad&#305;&#287;&#305;
gï¿½sterilmi&#351;tir. P53 geninin ï¿½al&#305;&#351;mas&#305;n&#305; dï¿½zenleyen
ba&#351;ka genler de mevcuttur: bunlardan 12. kromozomda bulunan MDM2 geni P53
geninin i&#351;levini bask&#305;lar. Yine, 6. kromozomda yer alan sikline
ba&#287;&#305;ml&#305; kinaz (CDK) genleri taraf&#305;ndan kodlanan P21
proteini hï¿½cre siklusunu durdurur. Bunlar d&#305;&#351;&#305;nda hï¿½cre siklusu
ï¿½zerine etkili proteinleri kodlayan birï¿½ok ba&#351;ka gen de tan&#305;mlanm&#305;&#351;t&#305;r.
Neoplazi olu&#351;umunda hï¿½cre siklusu ï¿½zerinde etkili genlerin
d&#305;&#351;&#305;nda, bï¿½yï¿½me faktï¿½rlerinin ve reseptï¿½rlerinin de rolï¿½
vard&#305;r. Bunlar aras&#305;nda epidermal bï¿½yï¿½me faktï¿½rï¿½ (EGF) ve reseptï¿½rï¿½
(EGFR), trombosit kaynakl&#305; bï¿½yï¿½me faktï¿½rï¿½ (PDGF) ve reseptï¿½rï¿½ (PDGFR),
fibroblast bï¿½yï¿½me faktï¿½rï¿½ (FGF) ve damar endotel bï¿½yï¿½me faktï¿½rï¿½ (VEGF)
say&#305;labilir. Hï¿½cre geli&#351;iminde rol oynayan bu bï¿½yï¿½me faktï¿½rlerinin
anormal derecede artmas&#305; hï¿½cre iï¿½i sinyal iletimi ile mitozu
artt&#305;rmaktad&#305;r. Tï¿½mï¿½rlerde genellikle hem bï¿½yï¿½me faktï¿½rlerini hem de
reseptï¿½rlerini kodlayan genlerde art&#305;&#351; oldu&#287;u gï¿½zlenmektedir.
Bunlar&#305;n d&#305;&#351;&#305;nda henï¿½z geni ve kodlad&#305;&#287;&#305;
proteini belirlenmemi&#351; baz&#305; kromozom bozukluklar&#305; da
tan&#305;mlanm&#305;&#351;t&#305;r. Bï¿½tï¿½n bu say&#305;lanlardan ba&#351;ka
apoptozun neoplazi geli&#351;imindeki rolï¿½ de ortaya konmu&#351;tur. Apoptozda
rol oynayan ba&#351;l&#305;ca iki yol vard&#305;r: birincisi hï¿½cre yï¿½zeyinde
bulunan FAS molekï¿½lï¿½ ve buna kar&#351;&#305; gelen FAS ligand&#305; (FASL),
ikincisi de hï¿½cre iï¿½inde bulunan BAX ve BCL-2 proteinleri. FAS ve BAX apoptozu
indï¿½klerken BCL-2 apoptozu ï¿½nler. Daha ï¿½nce sï¿½zï¿½ edilen P 53 proteini de FAS ve
BAX aktivasyonu yaparken, BCL-2ï¿½yi bask&#305;lar. Apoptoz yetene&#287;inin
kayb&#305; hem neoplazi geli&#351;imini indï¿½kler, hem de tedaviye direnï¿½
sa&#287;lar. Bu nedenle pro-apoptotik proteinlerin artt&#305;r&#305;lmas&#305;
yak&#305;n gelecekte birincil tedavi hedeflerindan biri haline gelebilir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Bu molekï¿½ler genetik bilgilerin &#305;&#351;&#305;&#287;&#305;nda
viruslar&#305;n hï¿½cre iï¿½ine onkogenleri ta&#351;&#305;yarak tï¿½mï¿½r
geli&#351;iminde ï¿½nemli rolï¿½ olabilece&#287;i dï¿½&#351;ï¿½nï¿½lmektedir.
Ebstein-Barr virusu ile lenfoma aras&#305;ndaki ili&#351;ki bilinmektedir.
Primer beyin tï¿½mï¿½rlerinde direkt kan&#305;t olmamakla birlikte Ebstein-Barr
virusu, hepatit-B virusu, insan papilloma virusu ve insan T-lenfosit virusu
gibi ajanlar suï¿½lanmaktad&#305;r. Ancak bï¿½yle bir ili&#351;ki henï¿½z
kan&#305;tlanmam&#305;&#351;t&#305;r. Bunun d&#305;&#351;&#305;nda kranyal
&#305;&#351;&#305;nlaman&#305;n hem meningiom hem de glial tï¿½mï¿½rlerin
geli&#351;me riskini artt&#305;rd&#305;&#287;&#305; gï¿½sterilmi&#351;tir.
Ayr&#305;ca, petrokimya ï¿½rï¿½nleri ve elektromanyetik dalgalar&#305;n beyin
tï¿½mï¿½rï¿½ riskini artt&#305;rd&#305;&#287;&#305; ileri sï¿½rï¿½lmï¿½&#351;se de bunun
aksini gï¿½steren ï¿½al&#305;&#351;malar da mevcuttur. ï¿½zellikle son y&#305;llarda
yayg&#305;n olarak kullan&#305;lan cep telefonlar&#305;n&#305;n etkisi
tart&#305;&#351;&#305;lmaktad&#305;r. Cep telefonu kullan&#305;m&#305; ile
baz&#305; beyin tï¿½mï¿½rlerinin s&#305;kl&#305;&#287;&#305;nda art&#305;&#351;
olabilece&#287;ini dï¿½&#351;ï¿½ndï¿½ren baz&#305; ï¿½al&#305;&#351;malar mevcuttur.
Ancak, 9 de&#287;i&#351;ik olgu-kontrol ï¿½al&#305;&#351;mas&#305;n&#305;n
meta-analizinde bugï¿½n iï¿½in bï¿½yle bir risk olmad&#305;&#287;&#305;
gï¿½sterilmi&#351;tir, uzun vadedeki etkileri zaman iï¿½inde tam olarak
netle&#351;ecektir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Gliomlar</span></b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'> </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Dï¿½&#351;ï¿½k
gradl&#305; diffï¿½z astrositomlar: </span></i></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>WHO
s&#305;n&#305;flamas&#305;na gï¿½re grad 2 dï¿½zeyindeki astrositik tï¿½mï¿½rler bu
gruba girer. Yï¿½ksek differansiyasyon gï¿½sterir, sadece nï¿½kleer atipi
vard&#305;r, yava&#351; bï¿½yï¿½r ancak ï¿½evre dokulara yayg&#305;n infiltrasyon
gï¿½sterir. Genellikle 30-40 ya&#351; aras&#305; genï¿½ eri&#351;kinlerde
s&#305;kt&#305;r. Yerle&#351;im s&#305;kl&#305;&#287;&#305;
aï¿½&#305;s&#305;ndan, supratentoriyal bï¿½lge birinci, beyinsap&#305; ise ikinci
s&#305;ray&#305; al&#305;r. Nï¿½roradyolojik olarak genellikle
s&#305;n&#305;rlar&#305; belirsiz, solid, pek kontrast tutmayan bir kitle
olarak gï¿½rï¿½lï¿½r. BTï¿½de hipodens, MRGï¿½de T1 a&#287;&#305;rl&#305;kl&#305;
kesitlerde hipointens, T2 a&#287;&#305;rl&#305;kl&#305; kesitlerde hiperintens
gï¿½rï¿½nï¿½r. Tedavi, tï¿½mï¿½r yerle&#351;imi riskli degilse, tï¿½mï¿½rï¿½n cerrahi olarak
ï¿½&#305;kar&#305;lmas&#305; &#351;eklindedir; mï¿½mkï¿½n oldu&#287;unca geni&#351;
total rezeksiyon hedeflenir. Ek olarak radyoterapinin gereklili&#287;i
tart&#305;&#351;mal&#305; bir konudur; cerrahi olarak ula&#351;&#305;lmas&#305;
gï¿½ï¿½ olan tï¿½mï¿½rlerde veya radyolojik olarak tï¿½mï¿½r nï¿½ksï¿½ veya progresyonu
saptanmas&#305; halinde mutlaka uygulan&#305;r. Dï¿½&#351;ï¿½k gradl&#305;
astrositomlarda kemoterapinin yerinin olmad&#305;&#287;&#305; dï¿½&#351;ï¿½nï¿½lï¿½rdï¿½,
ancak son y&#305;llarda ï¿½zellikle ï¿½ocuklarda veya geni&#351; tï¿½mï¿½rlerde yeri
olabilece&#287;i gï¿½sterilmi&#351;tir. Cerrahi sonras&#305;nda ortalama
sa&#287;kal&#305;m sï¿½resi 6-8 y&#305;ld&#305;r. Bazen zaman iï¿½inde daha habis
formlara dï¿½nï¿½&#351;ï¿½m gï¿½rï¿½lebilir. Bu dï¿½nï¿½&#351;ï¿½mde P53 genindeki
mutasyonlar&#305;n rol oynad&#305;&#287;&#305; dï¿½&#351;ï¿½nï¿½lmektedir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Anaplastik
astrositom:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> WHO s&#305;n&#305;flamas&#305;na gï¿½re grad 3 dï¿½zeyindeki astrositik
tï¿½mï¿½rler bu gruba girer. ï¿½Malignï¿½ astrositom veya yï¿½ksek gradl&#305; astrositom
ad&#305; da verilir. Fokal veya yayg&#305;n anaplazinin yan&#305; s&#305;ra,
yo&#287;un proliferasyon ve ï¿½evre dokulara yayg&#305;n infiltrasyon gï¿½sterir.
Ba&#351;lang&#305;ï¿½ ya&#351;&#305; dï¿½&#351;ï¿½k gradl&#305; astrositomlara oranla
daha geï¿½tir (ortalama 41 ya&#351;) ve daha h&#305;zl&#305; ilerler. Genellikle
serebral hemisferlerde yerle&#351;im gï¿½sterir. Nï¿½roradyolojik olarak
s&#305;n&#305;rlar&#305; belirsiz, solid bir kitle olarak gï¿½rï¿½lï¿½r. BTï¿½de
hipodens, MRGï¿½de T1 a&#287;&#305;rl&#305;kl&#305; kesitlerde hipointens, T2
a&#287;&#305;rl&#305;kl&#305; kesitlerde hiperintens gï¿½rï¿½nï¿½r. Dï¿½&#351;ï¿½k
gradl&#305; astrositomlar&#305;n tersine k&#305;smen kontrast tutulumu
vard&#305;r ve ï¿½dem etkisi daha belirgindir. Tedavi yï¿½z gï¿½ldï¿½rï¿½cï¿½ olmamakla
birlikte 40 ya&#351; alt&#305; genï¿½ hastalarda 1.5 y&#305;ll&#305;k
sa&#287;kal&#305;m oran&#305; % 60 civar&#305;ndad&#305;r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Glioblastoma
multiforme:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> En ï¿½malignï¿½ astrositik tï¿½mï¿½rdï¿½r (WHO s&#305;n&#305;flamas&#305;na gï¿½re
grad 4). ï¿½ok az differansiyasyon gï¿½sterir, yo&#287;un mitoz, damar
proliferasyonu ve nekroz iï¿½erir, ï¿½evre dokulara yo&#287;un infiltrasyon
vard&#305;r. Eri&#351;kinlerde en s&#305;k gï¿½rï¿½len beyin tï¿½mï¿½rï¿½dï¿½r. Genellikle
45-70 ya&#351; aras&#305; eri&#351;kinlerde s&#305;kt&#305;r (ortalama 53
ya&#351;), ancak daha genï¿½lerde de gï¿½rï¿½lebilir. H&#305;zl&#305; ilerler.
Genellikle supratentoriyal yerle&#351;im gï¿½sterir; frontotemporal veya
pariyetal yerle&#351;im s&#305;kt&#305;r; bazal ganglia bï¿½lgesine ve korpus
kallosumdan kar&#351;&#305; hemisfere geï¿½i&#351; s&#305;kt&#305;r; buna kelebek
gliomu ad&#305; da verilir. Makroskopik veya mikroskopik olarak multifokal
olabilir. Nï¿½roradyolojik olarak dï¿½zensiz s&#305;n&#305;rl&#305;, ortas&#305;nda
nekrotik kavite bulunan, ï¿½evresinde halkasal dï¿½zensiz kontrast tutulumu
gï¿½steren bir kitle olarak gï¿½rï¿½lï¿½r. Etraf&#305; ï¿½demlidir. Bazen BOSï¿½ta protein
art&#305;&#351;&#305;na ve lenfositik pleositoza yol aï¿½abilir. Nadiren de
meningial gliomatosis gï¿½rï¿½lebilir. MSS d&#305;&#351;&#305;na yay&#305;l&#305;m
ï¿½ok nadirdir. Prognozu kï¿½tï¿½dï¿½r; 1 y&#305;ll&#305;k sa&#287;kal&#305;m
oran&#305; % 20, 2 y&#305;ll&#305;k sa&#287;kal&#305;m ise % 10
civar&#305;ndad&#305;r. Tï¿½mï¿½rï¿½n tamam&#305;n&#305;n cerrahi olarak
ï¿½&#305;kar&#305;lmas&#305; genellikle mï¿½mkï¿½n olmamaktad&#305;r, ancak kitlenin
azalt&#305;lmas&#305; aï¿½&#305;s&#305;ndan yararl&#305;d&#305;r. Ek olarak
radyoterapi ve kemoterapi yap&#305;l&#305;r. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>ï¿½zellikle tï¿½mï¿½rï¿½ bï¿½yï¿½k oranda ï¿½&#305;kar&#305;labilmi&#351;, genï¿½ ve genel
durumu iyi hastalarda oral temozolamid ile kemoterapi sa&#287;kal&#305;m
&#351;ans&#305;n&#305; artt&#305;rabilir. Son y&#305;llarda
O-metilguanin-DNA-metil transferaz (MGMT) geni promoter bï¿½lgesinin
metillenmi&#351; olmas&#305;n&#305;n temozolamid ve radyoterapiye cevab&#305;
ï¿½nemli oranda artt&#305;rd&#305;&#287;&#305;na dair veriler elde
edilmi&#351;tir. Radyoaktif/kemoterapï¿½tik implantlar ve stereotaktik radyocerrahi
de denenmektedir. Bunlar&#305;n d&#305;&#351;&#305;nda son y&#305;llarda
giderek artan s&#305;kl&#305;kta hedefli biyolojik tedaviler
kullan&#305;lmaktad&#305;r. Yï¿½ksek gradl&#305; glial tï¿½mï¿½rler angiogenik
yap&#305;lar&#305; ï¿½ok gï¿½ï¿½lï¿½ tï¿½mï¿½rlerdir. Bu nedenle son y&#305;llarda
yap&#305;lan ï¿½al&#305;&#351;malarda ï¿½zellikle tï¿½mï¿½rï¿½n yeni damar yapma
potansiyelini hedefleyen yakla&#351;&#305;mlar daha popï¿½ler olmu&#351;tur.
Tï¿½mï¿½rï¿½n yeni damar yapmas&#305;ndan sorumlu temel molekï¿½ller VEFG (ï¿½vascular
endothelial growth factorï¿½) ve VEGF reseptï¿½rleridir. Klinikte; ï¿½evrede bulunan
VEGFï¿½i ba&#287;layarak etkinli&#287;ini azaltan humanize monoklonal antikor
bevacizumab ve VEGFR 1 ve 2ï¿½yi bloke eden reseptï¿½r tirozin kinaz inhibitï¿½rleri
(sorafenib ve sunatinib) bulunmaktad&#305;r. Bu tedavilerde hedef tï¿½mï¿½r hï¿½cresi
de&#287;il tï¿½mï¿½rï¿½n mikro ï¿½evresidir. Bu ajanlar&#305;n kemoterapi ilaï¿½lar&#305;n&#305;n
dokuya penetrasyonlar&#305;n&#305; artt&#305;rd&#305;&#287;&#305; da
gï¿½sterilmi&#351;tir ve bevacizumab glioblastoma multiforme tedavisinde FDA
onay&#305; alm&#305;&#351;t&#305;r. Yï¿½ksek gradl&#305; glial tï¿½mï¿½rlerde
hedeflenen di&#287;er genetik yollar aras&#305;nda EGFR (ï¿½epidermal growth
factorï¿½), mTOR, P 53, PI3K say&#305;labilir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Pilositik
astrositom:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Dï¿½&#351;ï¿½k gradl&#305; astrositomlar aras&#305;ndad&#305;r (WHO grade 1),
ancak ï¿½ok net s&#305;n&#305;rlar&#305;n&#305;n olmas&#305; nedeniyle
farkl&#305; kategoride ele al&#305;n&#305;r. Genellikle kistik komponenti
vard&#305;r. ï¿½o&#287;unlukla ilk iki ony&#305;lda olmak ï¿½zere ï¿½ocuklarda ve genï¿½
eri&#351;kinlerde s&#305;kt&#305;r. MSSï¿½nin pek ï¿½ok bï¿½lgesinde gï¿½rï¿½lebilir. En
s&#305;k gï¿½rï¿½ldï¿½&#287;ï¿½ lokalizasyonlar: optik sinirler (optik sinir gliomu),
optik kiazma-hipotalamus (kiazmatik/ hipotalamik gliom), talamus-bazal ganglia,
serebellum, beyinsap&#305;, serebral hemisferler, daha nadiren de medulla
spinalis olabilir. Nï¿½roradyolojik olarak s&#305;n&#305;rlar&#305; belirgin ve
genellikle kontrast tutan bir kitle olarak gï¿½rï¿½lï¿½r. Kistik ï¿½zellik gï¿½stermesi
tan&#305;y&#305; kolayla&#351;t&#305;r&#305;r. Yava&#351; bï¿½yï¿½r, bazen stabilize
olabilir hatta gerileyebilir. Malign transformasyon gï¿½stermez. ï¿½ok nadiren BOS
yoluyla yay&#305;labilir. Nadiren ï¿½lï¿½mcï¿½ldï¿½r. Cerrahi tedavi sonras&#305;nda
serebellar astrositomlu hastalar&#305;n %10ï¿½unun 20-30 y&#305;l
ya&#351;ad&#305;&#287;&#305; bildirilmi&#351;tir. Genetik yatk&#305;nl&#305;k
sï¿½z konusu olabilir: Tip 1 nï¿½rofibromatozlu hastalarda en s&#305;k gï¿½rï¿½len MSS
tï¿½mï¿½rï¿½dï¿½r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Oligodendrogliom:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Ba&#351;l&#305;ca
oligodendroglial hï¿½crelere benzeyen hï¿½crelerce olu&#351;turulan diffï¿½z
infiltratif bir tï¿½mï¿½rdï¿½r. WHO s&#305;n&#305;flamas&#305;na gï¿½re grad 2
dï¿½zeyindedir. Grad 3 oldu&#287;unda, yani nï¿½kleer atipi, hï¿½cresel
ï¿½e&#351;itlilik ve mitotik aktivite artt&#305;&#287;&#305;nda anaplastik
oligodendrogliom ad&#305;n&#305; al&#305;r; bu durumda bazen vaskï¿½ler
proliferasyon ve nekroz da gï¿½sterebilir. Bunlar&#305;n d&#305;&#351;&#305;nda
hem astrositik hem oligodendrositik hï¿½crelerden kaynaklanan oligoastrositomlar
da mevcuttur. Oligodendrogliomlar genellikle 3.- 4. ony&#305;lda gï¿½rï¿½lï¿½rse de
bazen ï¿½ocuklarda da gï¿½rï¿½lebilir. Anaplastik oligodendrogliom ise 4.-5.
ony&#305;lda daha s&#305;kt&#305;r. Oligodendrogliomlar s&#305;kl&#305;kla
frontal ve temporal bï¿½lgede derin ak maddede yerle&#351;ir. Nï¿½roradyolojik
olarak kitle etkisi olan, BTï¿½de hipo veya izodens gï¿½rï¿½nen, kalsifikasyon
gï¿½sterebilen, MRGï¿½de T1 a&#287;&#305;rl&#305;kl&#305; kesitlerde hipointens, T2
a&#287;&#305;rl&#305;kl&#305; kesitlerde hiperintens gï¿½rï¿½nen ve
s&#305;n&#305;rlar&#305; belirgin olan lezyon gï¿½rï¿½lï¿½r. Hafif kontrast
tutabilir, etraf&#305; ï¿½demlidir. Bazen tï¿½mï¿½r iï¿½ine kanama veya kist
bulunabilir. ï¿½zellikle anaplastik formda nekrotik kist, kanama, kalsifikasyon
ve kontrast tutulumu daha belirgindir. ï¿½ok nadiren oligodendrogliomlar BOS
yoluyla yay&#305;labilir. Tedavide genellikle iyi diferansiye tï¿½mï¿½rlerde cerrahi
yeterlidir; anaplastik olanlarda cerrahinin ard&#305;ndan radyoterapi ve bazen
kemoterapi uygulan&#305;r. Oligodendrogliomda rezeksiyon sonras&#305; ortalama
sa&#287;kal&#305;m yakla&#351;&#305;k 4.5 y&#305;l iken, anaplastik formda
biraz daha k&#305;sad&#305;r. ï¿½zellikle kromozom 1p ve 19q alelik kayb&#305; bulunan
tï¿½mï¿½rlerin kemosensitif olmalar&#305; dolay&#305;s&#305;yla tï¿½mï¿½rï¿½n bu yï¿½nden
incelenmesi mï¿½mkï¿½n olursa prognostik ï¿½nem ta&#351;&#305;yabilir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Ependimom:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Ventrikï¿½lleri kaplayan
ependimal tabakadan kaynaklanan tï¿½mï¿½rlerdir. WHO s&#305;n&#305;flamas&#305;na
gï¿½re grad 2 olan tï¿½mï¿½rlere ependimom ad&#305; verilir; grad 3 dï¿½zeyindeki, yani
nï¿½kleer atipi, hï¿½cresel ï¿½e&#351;itlilik ve artm&#305;&#351; mitotik aktivite
gï¿½steren, bazen vaskï¿½ler proliferasyon ve nekroz da iï¿½erebilen tï¿½mï¿½rlere
anaplastik ependimom ad&#305; verilir. Bunlar&#305;n d&#305;&#351;&#305;nda WHO
s&#305;n&#305;flamas&#305;na gï¿½re grad 1 olan iki tï¿½mï¿½r tipi daha vard&#305;r:
subependimom ve sadece kauda-konus bï¿½lgesinde yerle&#351;en miksopapiller
ependimom. Ependimomlar 1 ay-81 ya&#351; aras&#305;nda bï¿½tï¿½n ya&#351;
gruplar&#305;nda gï¿½rï¿½lebilir. Ependimomlar ventrikï¿½llerin herhangi bir bï¿½lgesinde
yer almakla birlikte en s&#305;k 4. ventrikï¿½lden kaynaklan&#305;r. Medulla
spinalisin en s&#305;k rastlanan glial tï¿½mï¿½rï¿½ de ependimomdur ve genellikle
lumbosakral bï¿½lgede yer al&#305;r. Bu da&#287;&#305;l&#305;m ya&#351;a gï¿½re
de&#287;i&#351;ir. &#304;nfratentoriyal yerle&#351;im ï¿½ocuklarda daha s&#305;k
gï¿½rï¿½lï¿½rken, eri&#351;kinlerde spinal ve infratentoriyal yerle&#351;im e&#351;it
orandad&#305;r. Nï¿½roradyolojik gï¿½rï¿½nï¿½mï¿½; s&#305;n&#305;rlar&#305; dï¿½zgï¿½n bir
kitle &#351;eklindedir. Kistik komponenti olabilir, de&#287;i&#351;en oranlarda
kontrast tutabilir. Hidrosefali s&#305;k gï¿½rï¿½lï¿½r. Bazen kom&#351;u normal nï¿½ral
dokuyu infiltre eder. BOS yoluyla, tohumlama (seeding) tipi metastaz
yapmas&#305; s&#305;kt&#305;r. Son iki ï¿½zellik anaplastik formda s&#305;k
gï¿½rï¿½lï¿½r. Bazen uzak metastaz dahi gï¿½rï¿½lebilir. Tedavi olarak genellikle tï¿½mï¿½r
rezeksiyonuna ek olarak BOS yoluyla yay&#305;l&#305;ma kar&#351;&#305;
radyoterapi uygulanmaktad&#305;r. Ancak radyoterapi uygulanacak alan&#305;n
geni&#351;li&#287;i tart&#305;&#351;mal&#305;d&#305;r. Anaplastik formda
kemoterapi de eklenebilir. ï¿½ocuklarda prognoz kï¿½tï¿½ olmakla birlikte spinal
ependimomlarda prognoz oldukï¿½a iyidir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Medulloblastom:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Serebellumda
yerle&#351;en infiltratif ve malign bir ilkel nï¿½roektodermal tï¿½mï¿½rdï¿½r. WHO
s&#305;n&#305;flamas&#305;na gï¿½re grad 4 dï¿½zeyindedir. &#304;lkel
nï¿½roektodermal tï¿½mï¿½rlerin ortak bir ï¿½ncï¿½ hï¿½creden kaynakland&#305;&#287;&#305;
dï¿½&#351;ï¿½nï¿½ldï¿½&#287;ï¿½nden farkl&#305; MSS hï¿½cre gruplar&#305;na do&#287;ru
farkl&#305;la&#351;ma gï¿½sterirler. En s&#305;k 7 ya&#351; civar&#305; olmak
ï¿½zere genellikle ï¿½ocukluk ï¿½a&#287;&#305;nda ortaya ï¿½&#305;kar ve
hastalar&#305;n ï¿½ï¿½te ikisi erkektir. ï¿½o&#287;unlukla vermiste yerle&#351;im
gï¿½sterir ve 4. ventrikï¿½le uzan&#305;r. Nï¿½roradyolojik olarak yo&#287;un ve
homojen kontrast tutulumu gï¿½steren solid kitle &#351;eklinde gï¿½rï¿½lï¿½r.
Leptomeningial yay&#305;l&#305;m s&#305;kt&#305;r ve bu da meninkslerde nodï¿½ler
veya yayg&#305;n kontrast tutulumuna yol aï¿½ar. Tedavide genellikle cerrahinin
ard&#305;ndan radyoterapi uygulan&#305;r. Bu tedavi ile 10 y&#305;ll&#305;k
sa&#287;kal&#305;m oran&#305; yakla&#351;&#305;k % 45 civar&#305;ndad&#305;r,
ancak ï¿½ok kï¿½ï¿½ï¿½k ï¿½ocuklarda radyoterapiden
kaï¿½&#305;n&#305;ld&#305;&#287;&#305;ndan bu olgularda kemoterapi
uygulan&#305;r. Ya&#351;&#305;n kï¿½ï¿½ï¿½k olmas&#305;, cerrahi rezeksiyonun tam
olmamas&#305; ve BOS yoluyla yay&#305;l&#305;m bulunmas&#305; kï¿½tï¿½ prognoz
i&#351;aretleridir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Meningiom:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Meningiomlar
araknoidal (meningotelyal) hï¿½crelerden kaynaklanan iyi huylu tï¿½mï¿½rlerdir.
Genellikle WHO grad 1 dï¿½zeyindedir; nadiren atipik veya anaplastik meningiom
gï¿½rï¿½lebilir (s&#305;ras&#305; ile WHO grad 2 ve 3). En s&#305;k 6. ve 7.
ony&#305;llarda gï¿½rï¿½lï¿½r. Hastalar&#305;n ï¿½ï¿½te ikisi kad&#305;nd&#305;r. Ailevi
olgular vard&#305;r. ï¿½zellikle tip 2 nï¿½rofibromatozda meningiomlar geli&#351;ir.
Meningiomlar araknoidal k&#305;l&#305;f&#305;n her bï¿½lgesinden kaynaklanabilir.
En s&#305;k falks yerle&#351;imlidir. S&#305;k gï¿½rï¿½ldï¿½&#287;ï¿½ di&#287;er
bï¿½lgeler olfaktï¿½r yar&#305;k, sfenoid ï¿½&#305;k&#305;nt&#305;, parasellar bï¿½lge,
optik sinirler, petroz ï¿½&#305;k&#305;nt&#305;, serebellar tentoryum ve arka
ï¿½ukurdur. Spinal kanalda en s&#305;k dorsal bï¿½lgede yer al&#305;r. Meningiomlar
ï¿½ok yava&#351; bï¿½yï¿½r ve bulundu&#287;u bï¿½lgeye gï¿½re de&#287;i&#351;mekle
birlikte, ï¿½ok bï¿½yï¿½medikï¿½e belirti vermeyebilir. Nï¿½roradyolojik olarak
kalsifikasyonlar gï¿½steren ve kontrast tutan izodens bir kitle olarak gï¿½rï¿½lï¿½r;
genellikle dura ile birle&#351;ti&#287;i yerde bir ï¿½dural kuyrukï¿½ bulunur.
Etraf&#305; ï¿½demlidir. Tï¿½mï¿½rï¿½n cerrahi olarak ï¿½&#305;kar&#305;lmas&#305;
kal&#305;c&#305; tedavi sa&#287;lar. Cerrahi giri&#351;imin mï¿½mkï¿½n
olmad&#305;&#287;&#305; hastalarda ve malign meningiomlarda radyoterapi
yap&#305;labilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nï¿½roma:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Bu grupta yer alan
Schwannoma ve nï¿½rofibroma WHO s&#305;n&#305;flamas&#305;nda grad 1 dï¿½zeyinde
iyi huylu periferik sinir tï¿½mï¿½rleridir. ï¿½ok daha nadir olarak malign
formlar&#305; gï¿½rï¿½lebilir. Bu iki tï¿½mï¿½r tipi de ailevi MSS tï¿½mï¿½rï¿½
sendromlar&#305;nda s&#305;k gï¿½rï¿½len tï¿½mï¿½rlerdir. Birincisi periferik siniri
ï¿½evreleyen iyi diferansiye Schwann hï¿½crelerinden olu&#351;ur; ikincisinde ise
Schwann hï¿½crelerinin yan&#305; s&#305;ra, perinï¿½ral-benzeri hï¿½creler,
fibroblastlar ve di&#287;er hï¿½creler de bulunur. Schwannomalar 4.-6.
ony&#305;llar aras&#305;nda s&#305;k olmakla beraber her ya&#351; grubunda
gï¿½rï¿½lebilir; nï¿½rofibroma da her ya&#351; grubunda gï¿½rï¿½lebilir. Schwannoma
genellikle ba&#351;-boyun bï¿½lgesindeki ve ekstremitelerin ekstansï¿½r
taraflar&#305;ndaki sinirlerden kaynaklan&#305;r. Spinal kï¿½klerde ve kranyal
sinirlerde de s&#305;kt&#305;r. ï¿½zellikle VIII. kranyal sinirde Schwannoma
s&#305;k gï¿½rï¿½lï¿½r (vestibï¿½ler nï¿½rinom/ akustik nï¿½rinom gibi); bu durumda
serebello-pontin kï¿½&#351;e sendromu bulgular&#305; ortaya ï¿½&#305;kar
(Bak&#305;n&#305;z: <span style='color:#4F81BD'><a href="../semi2/cranial.htm">Kranyal
sinirler: k&#305;sa anatomi-fizyoloji, muayene ve bozukluklar&#305;,</a></span>
<span style='color:#4F81BD'><a
href="../kranyalnoropatiler/Kranyalnoropatiler.html">Kranyal Nï¿½ropatiler</a></span>
). Nï¿½rofibroma ise kranyal sinirlerde gï¿½rï¿½lmez. Genellikle bir cilt nodï¿½lï¿½
&#351;eklindedir, bazen cilt ve ciltalt&#305;n&#305; yayg&#305;n olarak tutar
ve bï¿½tï¿½n ekstremitenin bï¿½yï¿½k gï¿½rï¿½nmesine yol aï¿½ar (elephantiasis neuromatosa).
Kranyal sinirlere ait Schwannoma MRGï¿½de dï¿½zgï¿½n s&#305;n&#305;rl&#305;, bazen
kistik komponentli, kemikte erozyon yapm&#305;&#351; bir kitle olarak gï¿½rï¿½lï¿½r;
homojen kontrast tutan bu tip tï¿½mï¿½rlerin tedavisi cerrahidir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kranyofaringiom:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> ï¿½ocuklarda ve
genï¿½lerde gï¿½rï¿½len iyi huylu bir epitelyal tï¿½mï¿½rdï¿½r (WHO grad 1). Rathke kesesi
kal&#305;nt&#305;lar&#305;ndan geli&#351;ti&#287;i dï¿½&#351;ï¿½nï¿½lï¿½r. Genellikle
suprasellar yerle&#351;imlidir; bazen sella iï¿½ine de uzan&#305;r. Optik kiazma
bas&#305;s&#305;na ba&#287;l&#305; gï¿½rme yak&#305;nmalar&#305; ve endokrin bozukluklarla
kendini gï¿½sterir. Heterojen gï¿½rï¿½nï¿½mde yer yer kistik ve yer yer kalsifikasyonlu
bir tï¿½mï¿½rdï¿½r. Solid k&#305;s&#305;mlar&#305; kontrast tutar. BTï¿½de
kalsifikasyonlar hiperdens gï¿½rï¿½nï¿½r. Kolesterol iï¿½eren bir tï¿½mï¿½r oldu&#287;undan
MRGï¿½de kontrasts&#305;z T1 a&#287;&#305;rl&#305;kl&#305; kesitlerde yer yer
hiperintens gï¿½rï¿½nebilir. Tedavi cerrahidir; ancak her zaman tï¿½mï¿½rï¿½n tamam&#305;
ï¿½&#305;kar&#305;lamayabilir. Bu durumda nï¿½ksler s&#305;kt&#305;r. Radyoterapi
yap&#305;labilir, ancak yarar&#305; tart&#305;&#351;mal&#305;d&#305;r. Endokrin
bozuklu&#287;un dï¿½zeltilmesi ï¿½nemlidir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Primer Serebral Lenfoma</span></b><span lang=TR style='font-size:14.0pt;
font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Merkezi sinir
sisteminde lenfoma s&#305;kl&#305;kla metastatik olarak gï¿½rï¿½lï¿½r. Ancak daha
seyrek olarak ekstra-nï¿½ral bir odak olmaks&#305;z&#305;n sinir sisteminde
lenfoma geli&#351;ebilir. ï¿½nceki y&#305;llarda bu tï¿½mï¿½rlerin retikï¿½loendotelyal
sistemden kaynaklanan histiositik sarkom oldu&#287;u dï¿½&#351;ï¿½nï¿½lï¿½rdï¿½; bu
nedenle retikulum hï¿½creli sarkom veya mikrogliom gibi isimler verilmi&#351;ti.
Ancak daha sonra immunhistokimyasal yï¿½ntemlerin geli&#351;mesi ile bu tï¿½mï¿½rï¿½n
asl&#305;nda bir malign, non-Hodgkin lenfoma tipi oldu&#287;u gï¿½rï¿½ldï¿½. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Son
y&#305;llar iï¿½inde gï¿½rï¿½len primer serebral lenfoma
s&#305;kl&#305;&#287;&#305;nda belirgin bir art&#305;&#351; dikkati
ï¿½ekmektedir. ï¿½rne&#287;in 1970ï¿½lerde bï¿½tï¿½n MSS tï¿½mï¿½rleri aras&#305;nda
oran&#305; %1ï¿½in alt&#305;nda iken son 30 y&#305;lda
s&#305;kl&#305;&#287;&#305; belirgin olarak artm&#305;&#351;t&#305;r; baz&#305;
merkezlerde gï¿½rï¿½len her 5 veya 6 beyin tï¿½mï¿½rï¿½nden birini bunlar
olu&#351;turmaktad&#305;r. Amerika Birle&#351;ik Devletleriï¿½nde gï¿½rï¿½len bï¿½tï¿½n
primer MSS tï¿½mï¿½rlerinin yakla&#351;&#305;k %3ï¿½ï¿½nï¿½ primer MSS lenfomas&#305;
olu&#351;turur; bï¿½tï¿½n non-Hodgkin lenfomalar&#305;n ise yine %2-3ï¿½ï¿½nï¿½ oluturur.
MSS lenfomas&#305; insidensinde gï¿½rï¿½len art&#305;&#351;&#305;n ï¿½nemli bir
nedeni AIDSï¿½li veya transplantasyon nedeniyle immunsupresif tedavi gï¿½ren ve
di&#287;er nedenlerle immun yetersizli&#287;i olan hastalarda s&#305;k ortaya
ï¿½&#305;kmas&#305;d&#305;r. &#304;mmun yetersizli&#287;i olan hastalarda
serebral lenfoman&#305;n etyolojisinde Ebstein Barr virusunun rol oynad&#305;&#287;&#305;
dï¿½&#351;ï¿½nï¿½lmektedir. Ancak, son birkaï¿½ y&#305;ld&#305;r primer MSS
lenfomas&#305; s&#305;kl&#305;&#287;&#305;ndaki art&#305;&#351;&#305;n
duraklad&#305;&#287;&#305; da dikkati ï¿½ekmektedir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Primer
serebral lenfomalar&#305;n yakla&#351;&#305;k % 90ï¿½&#305; B-lenfosit
kï¿½kenlidir. T-lenfosit kï¿½kenli lenfomalar ï¿½ok daha nadirdir. &#304;mmun
yetersizli&#287;i olmayan hastalarda 6.-7. ony&#305;llarda ortaya ï¿½&#305;karken
konjenital immun yetersizli&#287;i olan ï¿½ocuklarda, 10 ya&#351; civar&#305;nda,
transplantasyon hastalar&#305; ve AIDSï¿½lilerde ise 3. ve 4. ony&#305;lda
s&#305;kt&#305;r. Genelde erkeklerde daha s&#305;k gï¿½rï¿½lï¿½r; AIDSï¿½lilerde ise
lenfomal&#305; hastalar&#305;n % 90ï¿½&#305; erkektir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>En s&#305;k
frontal lobda, giderek azalan s&#305;kl&#305;kta temporal, parietal ve
oksipital loblarda, arka ï¿½ukurda, bazal ganglia ve periventrikï¿½ler bï¿½lgede
(%10), korpus kallosumda, nadiren de omurilikte yerle&#351;ir. Leptomeningial
yay&#305;l&#305;m % 30-40 olguda gï¿½rï¿½lï¿½r. Primer intra-okï¿½ler lenfoma
&#351;eklinde gï¿½z tutulumu da gï¿½rï¿½lebilir. T-lenfosit lenfomas&#305; arka
ï¿½ukuru, ï¿½zellikle serebellumu daha fazla tutar; leptomeningial
yay&#305;l&#305;m da daha s&#305;kt&#305;r. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Uluslararas&#305;
MSS Lenfomas&#305; ï¿½al&#305;&#351;ma Grubunun yay&#305;nlad&#305;&#287;&#305;
k&#305;lavuza gï¿½re bu hastalar&#305;n de&#287;erlendirmesinde patolojik
inceleme ve immunfenotiplemenin yan&#305; s&#305;ra, ayr&#305;nt&#305;l&#305;
t&#305;bbi ve nï¿½rolojik muayene, HIV serolojisi, kontrastl&#305; kranyal MR,
gï¿½z muayenesi, serum LDH dï¿½zeyi, toraks-abdomen-pelvis BT incelemesi, kontrendikasyon
yoksa BOS sitolojisi, kemik ili&#287;i aspirasyon biyopsisi ve erkek hastalarda
testis muayene ve ultrasonu yap&#305;lmas&#305; ï¿½nerilmektedir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nï¿½roradyolojik
bulgular:</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> BTï¿½de hipodens veya izodens, MRGï¿½de hiperintens veya izointens gï¿½rï¿½nen tek
veya multipl lezyonlar gï¿½rï¿½lï¿½r. Genellikle solid olur, nadiren kistiktir.
S&#305;kl&#305;kla yayg&#305;n kontrast tutulumu gï¿½sterir. &#304;mmun
yetersizli&#287;i olan hastalarda halkasal kontrast tutulumu gï¿½rï¿½lebilir. Daha
ï¿½ok supratentoriyal yerle&#351;ir, periventrikï¿½ler yerle&#351;im
s&#305;kt&#305;r. Bilateral bazal ganglion bï¿½lgesinde kontrast tutan ayna
gï¿½rï¿½ntï¿½sï¿½nï¿½n patognomonik oldu&#287;u sï¿½ylenir. Tï¿½mï¿½r ile normal doku
aras&#305;ndaki s&#305;n&#305;r keskin de&#287;ildir, etraf&#305;ndaki ï¿½dem de
di&#287;er tï¿½mï¿½rlerde gï¿½rï¿½lenden daha azd&#305;r. Bazen leptomeningial kontrast
tutulumu gï¿½zlenebilir. Metastatik lenfomalar ise s&#305;kl&#305;kla
leptomeningial tutulum yapar, parenkim lezyonu nadirdir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>BOS:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Primer serebral
lenfomal&#305; olgular&#305;n % 35-60ï¿½&#305;nda pleositoz gï¿½rï¿½lï¿½r. Ancak sadece
sitoloji ile hastalar&#305;n sadece % 5 ila 30ï¿½una tan&#305; konabilir. Oysa
metastatik lenfomalar s&#305;kl&#305;kla leptomeningial tutulum
yapt&#305;&#287;&#305;ndan BOS sitolojisi % 70-95 oran&#305;nda tan&#305;
koydurucu olabilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Stereotaktik
biyopsi:</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Bugï¿½n tercih edilen tan&#305; yï¿½ntemidir. Ancak biyopsi ï¿½ncesinde kitleyi
kï¿½ï¿½ï¿½ltme ï¿½zellikleri nedeniyle kortikosteroid verilmesinden
kaï¿½&#305;n&#305;lmal&#305;d&#305;r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tedavi:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Cerrahi giri&#351;imin
tedavide yeri yoktur. Kortikosteroidler tï¿½mï¿½r hï¿½crelerinin tamamen
kaybolmas&#305;na yol aï¿½abilir. Ancak biyopsi planlan&#305;yorsa, biyopsinin
tan&#305;sal de&#287;erini azaltaca&#287;&#305;ndan, ï¿½ncesinde kortikosteroid
verilmemesi gerekti&#287;i unutulmamal&#305;d&#305;r. ï¿½nceleri tercih edilen
tedavi kranyal radyoterapi ile kombine edilen metotreksat bazl&#305; intravenï¿½z
kemoterapi idi. Ancak bu tedavinin yol aï¿½abilece&#287;i gecikmi&#351; serebral
toksisite nedeniyle bugï¿½n ya tek ba&#351;&#305;na kemoterapi ya da kemoterapi
ile kombine dï¿½&#351;ï¿½k doz kranyal radyoterapi kullan&#305;lmaktad&#305;r. MSS
penetrasyonu ï¿½ok yï¿½ksek bir oral alkilleyici ajan olan temezolamid de tek
ba&#351;&#305;na veya bir anti-CD 20 monoklonal antikor olan rituksimab ile
birlikte kullan&#305;labilmektedir. Ayr&#305;ca otolog kï¿½k hï¿½cre nakli ile
birlikte yï¿½ksek doz kemoterapi uygulanmas&#305;n&#305; ara&#351;t&#305;ran
ï¿½al&#305;&#351;malar da vard&#305;r. Ancak, bugï¿½ne dek herhangi bir tedavinin
di&#287;erine net olarak ï¿½stï¿½nlï¿½&#287;ï¿½ gï¿½sterilmemi&#351;tir. &#304;mmun
yetmezli&#287;i olan hastalarda ba&#287;&#305;&#351;&#305;kl&#305;k sistemini
gï¿½ï¿½lendirici yakla&#351;&#305;mlarda bulunulmal&#305;d&#305;r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Prognoz:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Tedaviye cevap
genellikle iyidir, ancak s&#305;kl&#305;kla tekrarlar gï¿½rï¿½lï¿½r. Tedavi
sonras&#305; ortalama sa&#287;kal&#305;m bir y&#305;l&#305; biraz a&#351;ar.
&#304;yi prognoz i&#351;aretleri immun yetersizlik bulunmamas&#305;, tek
intrakranyal lezyon, meningial ve/veya ventrikï¿½ler yay&#305;l&#305;m&#305;n
olmamas&#305;, ya&#351;&#305;n 60ï¿½&#305;n alt&#305;nda olmas&#305; ve
hastan&#305;n genel durumunun iyi olmas&#305;d&#305;r. Kemoradyoterapinin veya
tek ba&#351;&#305;na serebral radyoterapinin en ï¿½nemli yan etkisi nï¿½rotoksisitesidir;
ï¿½zellikle 60 ya&#351;&#305;n ï¿½zerindeki hastalarda daha s&#305;k gï¿½rï¿½len bu
durum progresif demans, ataksi ve inkontinans &#351;eklinde gï¿½rï¿½lï¿½r.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Di&#287;er Tï¿½mï¿½rler</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Daha ï¿½nce de belirtildi&#287;i gibi sinir sisteminin gï¿½rece s&#305;k
gï¿½rï¿½len tï¿½mï¿½rleri bu bï¿½lï¿½mï¿½n kapsam&#305; iï¿½ine al&#305;nd&#305;. Ancak
bunlar&#305;n d&#305;&#351;&#305;nda pek ï¿½ok farkl&#305; tï¿½mï¿½r vard&#305;r. Bunlar
aras&#305;nda ilkel nï¿½roektodermal tï¿½mï¿½rlerden nï¿½roblastoma, retinoblastoma,
vaskï¿½ler kï¿½kenli hemangioblastoma, pineal dokudan kaynaklanan pineoblastoma ve
pineositoma, nï¿½ronal kï¿½kenli nï¿½roblastoma, ganglionï¿½roma, ganglionï¿½roblastoma,
ilkel notokord kal&#305;nt&#305;s&#305;ndan geli&#351;en kordoma, kolloid
kistler, kolesteatoma, karotis bifurkasyonunda yerle&#351;en paraganglioma ve
glomus jugulare tï¿½mï¿½rï¿½ ile gï¿½rece s&#305;k gï¿½rï¿½len ve ortaya
ï¿½&#305;kard&#305;&#287;&#305; gï¿½rme bozukluklar&#305; ve nï¿½ro-endokrin
bozukluklarla tan&#305;nan ancak nï¿½ro-onkoloji kapsam&#305;
d&#305;&#351;&#305;nda ele al&#305;nmas&#305; gereken hipofiz tï¿½mï¿½rleri
say&#305;labilir. Okur bu konular&#305;n ayr&#305;nt&#305;lar&#305; iï¿½in
nï¿½ro&#351;irurji kitaplar&#305;na ba&#351;vurabilir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Ailesel MSS Tï¿½mï¿½rleri</span></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Eskiden beri
baz&#305; ailelerde tï¿½mï¿½r kï¿½melenmeleri oldu&#287;u biliniyordu. Son
y&#305;llarda molekï¿½ler genetik ï¿½al&#305;&#351;malar ile bunlar&#305;n
alt&#305;nda yatan genetik patoloji de ortaya konmu&#351;, bu da genel anlamda
kanser olu&#351;um mekanizmalar&#305;n&#305; daha iyi anlamam&#305;z&#305;
sa&#287;lam&#305;&#351;t&#305;r. Tï¿½mï¿½ otozomal dominant geï¿½i&#351; gï¿½steren bu
sendromlar <b>Tablo 3</b>ï¿½te s&#305;ralanm&#305;&#351;t&#305;r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nï¿½rofibromatosis
Tip I:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Von Recklinghausen hastal&#305;&#287;&#305; olarak da
adland&#305;r&#305;l&#305;r. Tan&#305; iï¿½in &#351;u kriterlerden en az ikisi
bulunmal&#305;d&#305;r: 1) ï¿½ap&#305; puberte ï¿½ncesinde &gt; 5mm, puberte
sonras&#305;nda &nbsp;&gt; 15 mm olan 6 veya daha fazla ï¿½cafï¿½ au laitï¿½ sï¿½tlï¿½
kahverenginde cilt lekesi; 2) iki veya daha fazla nï¿½rofibroma; 3) aksiller veya
inguinal ï¿½illenme; 4) optik sinir gliomu; 5) belirgin bir kemik lezyonu; 6)
birinci dereceden bir akrabada tip I nï¿½rofibromatosis bulunmas&#305;. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nï¿½rofibromatosis
Tip II:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Genetik olarak tip I nï¿½rofibromatosisden ayr&#305; bir tablodur ve <i>Von
Recklinghausen hastal&#305;&#287;&#305; olarak adland&#305;r&#305;lmaz.</i>
Tan&#305; kriterleri: 1) bilateral akustik nï¿½rinom (Schwannom); veya<i> </i>2)
birinci dereceden bir akrabada tip II nï¿½rofibromatosis bulunmas&#305;,
art&#305;, ya <i>a)</i> unilateral akustik nï¿½rinom, ya da<i> b) </i>a&#351;a&#287;&#305;dakilerden
ikisi: meningiom, Schwannom, gliom, nï¿½rofibrom, arka subkapsï¿½ler lens
opasitesi, serebral kalsifikasyon; veya 3) a&#351;a&#287;&#305;dakilerden
ikisi: <i>a)</i> unilateral akustik nï¿½rinom;<i> b)</i> multipl meningiom; <i>c)
</i>Schwannom, gliom, nï¿½rofibrom, arka subkapsï¿½ler lens opasitesi, serebral
kalsifikasyon. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp; <br>
&nbsp; </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<b><span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:TR;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always'>
</span></b>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>Tablo 3. Familyal MSS Tï¿½mï¿½rleri </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(Kaynak 22ï¿½den) </span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp; </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;background:#FFFFCC;mso-padding-alt:
 0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Sendrom&nbsp;</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;Gen&nbsp;</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Kromozom</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;Sinir sistemi&nbsp;</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Cilt</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;Di&#287;er</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nï¿½rofibromatosis I&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>NF1</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>17q11&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>nï¿½rofibromlar, MPNST,optik gliom, astrositom</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;ï¿½cafï¿½ au laitï¿½,aksiller ï¿½iller</span><span
  lang=FR style='mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>iris hamartomu, ossï¿½z,lezyonlar,, lï¿½semi,feokromasitoma</span><span
  lang=FR style='mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nï¿½rofibromatosis II</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;NF2&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>22q12&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>bilateral akustik nï¿½rinom, periferik nï¿½rinomlar
  (Schwannom), meningiomlar, spinal ependimomlar, astrositomlar, vs.</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp; (-)</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>arka lens opasitesi, retinal hamartom</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>von Hippel Lindau&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;VHL&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>3p25&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>hemangioblastom&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(-)</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>renal ca., retinal hemangioblastom, feokromasitoma,</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>organ kistleri</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Tuberoz Skleroz</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>TSC1</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>TSC2&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>9q34</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>16p13&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>subependimal dev hï¿½creli astrositom,&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>kortikal ï¿½tuberï¿½ler&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>anjiofibromlar</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>ï¿½peau chagrinï¿½, subungual&nbsp; fibrom</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>kardiyak rabdomiyom,</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>adenomatï¿½z G&#304;S&nbsp; akci&#287;er-&nbsp; bï¿½brek kistleri, vs.</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Li-Fraumeni&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>TP53</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>17p13&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>astrositomlar, PNET&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;(-)&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>meme ca., lï¿½semi,</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>kemik ve yumu&#351;ak doku</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>sarkomlar&#305;, adrenal korteks ca.</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Cowden&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>PTEN&nbsp;&nbsp; (MMAC1)&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>10q23&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>serebellumda displastik gangliositom</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>tri&#351;ilemmom, fibromlar</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>kolonda hamartomatï¿½z</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>polipler, tiroid tm,&nbsp;</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>meme ca.</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Turcot&nbsp;</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> <br>
  &nbsp; <br>
  &nbsp; </span></p>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>APC</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>hMLH1</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>hPSM2&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>5q21&nbsp;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>3p21&nbsp;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>7p22&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>medulloblastom</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>glioblastoma&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(-)</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>ï¿½cafï¿½ au laitï¿½</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>kolorektal polipler</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>kolorektal polipler</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nevoid bazal ca. sendromu&nbsp;</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>PTCH</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>9q31</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>medulloblastom</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;multipl bazal ca.</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>ï¿½ene kistleri, over fibromlar&#305;, iskelet
  anomalileri</span></p>
  </td>
 </tr>
</table>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>MPNST: malign periferik sinir k&#305;l&#305;f tï¿½mï¿½rï¿½, PNET: ilkel
nï¿½roektodermal tï¿½mï¿½r</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p><a name="Sistemik_Kanserin_Nï¿½rolojik"></a><b><span lang=TR style='font-size:
14.0pt;font-family:Tahoma;text-transform:uppercase;mso-ansi-language:TR'>Sistemik
Kanserin Nï¿½rolojik Etkileri</span></b><span lang=TR style='font-size:14.0pt;
font-family:Tahoma;text-transform:uppercase;mso-ansi-language:TR'> </span></p>

<p style='margin-top:0cm;margin-right:0cm;margin-bottom:12.0pt;margin-left:
0cm'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Sistemik
kanserin nï¿½rolojik komplikasyonlar&#305; nï¿½roloji ile u&#287;ra&#351;an hekimin
gï¿½nlï¿½k prati&#287;inde giderek artan s&#305;kl&#305;kta ve ï¿½nemli bir yer
tutmaktad&#305;r. Nï¿½fusun ya&#351; ortalamas&#305;n&#305;n artmas&#305;,
endï¿½striyel toksinlere daha fazla maruz kalma gibi nedenlerle kanser insidensi
giderek artmaktad&#305;r. Ayr&#305;ca, yeni tedavi yï¿½ntemlerinin geli&#351;mesi
ile kanserli hastalar&#305;n sa&#287; kal&#305;m sï¿½resi uzamakta, infeksiyon ve
metabolik sorunlarla ba&#351;a ï¿½&#305;kmada geli&#351;tirilen yeni yï¿½ntemler de
sa&#287;kal&#305;m ï¿½zerinde olumlu etki gï¿½stermektedir. Bunlara ba&#287;l&#305;
olarak zaman iï¿½inde gï¿½rï¿½lebilecek nï¿½rolojik problemler de artmaktad&#305;r.
Ayr&#305;ca kanserli hastalarda gï¿½rï¿½lebilen nï¿½rolojik komplikasyonlar
genellikle acilen mï¿½dahale edilmesi gereken ciddi, ancak tedavi ile k&#305;smen
de olsa rahatlat&#305;lmas&#305; mï¿½mkï¿½n olan sorunlard&#305;r. Bu nedenlerle
nï¿½roloji prati&#287;inde ï¿½nemli bir yeri vard&#305;r. Kanserli bir hastada
belirti veren sinir sistemi bï¿½lgesine gï¿½re aranmas&#305; gereken komplikasyon
tï¿½rleri<b> Tablo 4</b>ï¿½te verilmektedir. <br>
<a name="Direkt_tï¿½mï¿½r_yay&#305;l&#305;m&#305;na_ba&#287;l&#305;_(metastati"></a><br>
<b><span style='color:black'>Tablo 4. Kanserli hastada belirti veren bï¿½lgeye
gï¿½re aranmas&#305; gereken nï¿½rolojik komplikasyon tï¿½rleri </span></b></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(Kaynak
26ï¿½dan).</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;background:#FFFFCC;mso-padding-alt:
 0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>Bï¿½lge</span></b></p>
  </td>
  <td style='background:#FF6666;padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nï¿½rolojik komplikasyon</span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Beyin</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Parenkim
       metastaz&#305; </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Leptomeningial
       metastaz </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Metabolik ve
       toksik ensefalopati </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;nfeksiyon
       (menenjit, abse) </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Radyasyon
       ensefalopatisi </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Serebrovaskï¿½ler
       olay </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       (limbik ensefalopati, vs.) </span></li>
  </ul>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Omurilik &amp; kauda ekuina</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidural
       bas&#305; </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Leptomeningial
       metastaz </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;ntramedï¿½ller
       metastaz </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidural abse
       veya kanama </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Radyasyon
       miyelopatisi </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;ntratekal
       kemoterapiye ba&#287;l&#305; miyelopati </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       miyelopati </span></li>
  </ul>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Kranyal ve periferik sinir</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tï¿½mï¿½r veya
       di&#287;er kitlelere ba&#287;l&#305; bas&#305; </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tï¿½mï¿½r
       taraf&#305;ndan infiltrasyon </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kemoterapi
       toksisitesi </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Varisella zoster
       infeksiyonu </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Radyasyon
       pleksopatisi </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       nï¿½ropati </span></li>
  </ul>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Nï¿½romï¿½skï¿½ler bile&#351;ke</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;laï¿½lar
       (aminoglikozid antibiyotikler) </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik bozukluk
       (Lambert-Eaton miyastenik sendromu, miyastenia gravis) </span></li>
  </ul>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Kas</span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Steroid
       miyopatisi </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Ka&#351;ektik
       miyopati </span></li>
   <li class=MsoNormal style='mso-list:l16 level1 lfo9;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       polimiyozit / dermatomiyozit </span></li>
  </ul>
  </td>
 </tr>
</table>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><br>
</span><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Tï¿½mï¿½r Yay&#305;l&#305;m&#305;na Ba&#287;l&#305; (Metastatik) Etkiler</span></b><span
lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nï¿½rolojik
yak&#305;nmalar&#305; olan kanserli hastalar&#305;n yakla&#351;&#305;k
yar&#305;s&#305;nda bu yak&#305;nmalar do&#287;rudan tï¿½mï¿½r invazyonuna
ba&#287;l&#305;d&#305;r. Kanserli hastalar&#305;n yakla&#351;&#305;k % 25ï¿½inde
beyin parenkimine, dura veya meninkslere metastaz gï¿½rï¿½lï¿½r; % 5ï¿½inde ise spinal
metastaz vard&#305;r. Y&#305;lda 100 000 ki&#351;ilik nï¿½fus ba&#351;&#305;na
MSS metastaz&#305; ile giden hastal&#305;k oran&#305; 4 ile 11 aras&#305;nda
de&#287;i&#351;ir. Beyin metastaz&#305; s&#305;kl&#305;&#287;&#305; ya&#351;la
birlikte artar. Bunlar&#305;n d&#305;&#351;&#305;nda, do&#287;rudan MSSï¿½yi
tutmamakla birlikte kemik metastazlar&#305; da ï¿½zellikle medulla spinalis
bas&#305;lar&#305; yaratarak ï¿½nemli nï¿½rolojik sorunlara yol aï¿½abilmektedir.
ï¿½zetle, <i>kanserli oldu&#287;u bilinen bir hasta nï¿½rolojik tablo
geli&#351;tirdi&#287;i takdirde ï¿½ncelikle metastaz
olas&#305;l&#305;&#287;&#305; dï¿½&#351;ï¿½nï¿½lmelidir</i>. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Tï¿½mï¿½rï¿½n sinir sistemine ula&#351;mas&#305; ï¿½e&#351;itli yollardan olur.
Beyin parenkim metastazlar&#305;nda yay&#305;l&#305;m tï¿½rï¿½ hematojendir. Bu yollardan
biri olarak Batson venï¿½z pleksusundan da sï¿½z etmek gerekir: Batson venï¿½z
pleksusu olarak bilinen, vertebral venï¿½z pleksus pelvisten kranyal venï¿½z
sinï¿½slere uzanan ve kapakï¿½&#305;k iï¿½ermeyen bir sistemdir. Bu sistem
arac&#305;l&#305;&#287;&#305; ile iki yï¿½ne do&#287;ru da hematojen metastazlar
gerï¿½ekle&#351;ebilir. Leptomeningial metastaz ise perinï¿½ral lenfatikler
kanal&#305;yla ya da beyin metastazlar&#305;ndan BOSï¿½a dï¿½kï¿½len hï¿½creler<i> </i>sonucu
olu&#351;ur. Bunlar&#305;n d&#305;&#351;&#305;nda tï¿½mï¿½rï¿½n kendi kitlesinin veya
lenf nodu ya da uzak metastazlar&#305;n&#305;n ï¿½evre<i> </i>dokuyu infiltre
etmesi sï¿½z konusu olabilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:13.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Beyin Metastaz&#305;</span></b><span lang=TR style='font-size:13.0pt;
font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Beyin
metastaz&#305;n&#305;n en s&#305;k nedenleri akci&#287;er kanseri, melanom,
meme kanseri, renal kanser ve lenfoma gibi tï¿½mï¿½rler olmakla birlikte,
olgular&#305;n % 10ï¿½unda metastaz&#305;n kayna&#287;&#305; belirlenemez.
Di&#287;er yandan, ï¿½zellikle s&#305;k beyin metastaz&#305; yapan kanserler
de&#287;erlendirildi&#287;inde: melanomlar&#305;n % 75ï¿½i, testis kanserlerinin
% 57ï¿½si, akci&#287;er kanserlerinin % 35ï¿½i beyin metastaz&#305; yapar. Beyin
dokusuna hemen hiï¿½ metastaz yapmayan baz&#305; kanserler de vard&#305;r. Bunlar
aras&#305;nda prostat, ï¿½zofagus, orofarinks ve melanom d&#305;&#351;&#305; cilt
kanserleri yer al&#305;r. Buna kar&#351;&#305;n, prostat, meme kanseri, multipl
miyelom ve Hodgkin hastal&#305;&#287;&#305;, non-Hodgkin lenfoma ile birlikte
dural metastaz gï¿½rï¿½lï¿½r. Beyin parenkim metastazlar&#305;n&#305;n % 80ï¿½i
hemisferlerde % 20ï¿½si arka ï¿½ukurda yer al&#305;r; ancak pelvik organlar&#305;n
ve kolon kanserinin metastazlar&#305; arka ï¿½ukuru tercih eder. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Beyin
metastazlar&#305; di&#287;er tï¿½mï¿½rler gibi ba&#351;l&#305;ca kafa iï¿½i
bas&#305;nï¿½ art&#305;&#351;&#305; sendromu veya epileptik nï¿½betlerle
kar&#351;&#305;m&#305;za ï¿½&#305;karlar. Ayr&#305;ca bulunduklar&#305; bï¿½lgeye
ï¿½zgï¿½ belirtiler de verebilirler. Birden fazla say&#305;da (multipl)
olduklar&#305;nda tan&#305; gï¿½ï¿½lï¿½&#287;ï¿½ yarat&#305;rlar. Bazen de
davran&#305;&#351; de&#287;i&#351;ikli&#287;i, uyan&#305;kl&#305;k kusuru ve
silik nï¿½rolojik bulgularla genel bir ensefalopati tablosuna yol aï¿½abilirler. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nï¿½roradyoloji:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> BTï¿½de metastazlar
izodens veya hipodens dï¿½zgï¿½n s&#305;n&#305;rl&#305; lezyonlar olarak gï¿½rï¿½lï¿½r.
Yo&#287;un homojen veya ï¿½evresel kontrast tutulumu vard&#305;r, etraf&#305;
ï¿½demlidir. BTï¿½nin negatif olmas&#305; metastaz olas&#305;l&#305;&#287;&#305;n&#305;
ortadan kald&#305;rmaz, ku&#351;ku varsa MRG yap&#305;lmal&#305;d&#305;r.
Metastazlar MRGï¿½de T1 a&#287;&#305;rl&#305;kl&#305; kesitlerde hipointens, T2
a&#287;&#305;rl&#305;kl&#305; kesitlerde hiperintens gï¿½rï¿½nï¿½r. Belirgin kontrast
tutulumu gï¿½sterir. Metastatik lezyon say&#305;s&#305; da primer tï¿½mï¿½r tipi
hakk&#305;nda bilgi verebilir. Tek lezyon varsa, bï¿½brek, meme, tiroid,
akci&#287;er adenokarsinomu akla gelmelidir. Kï¿½ï¿½ï¿½k hï¿½creli akci&#287;er kanseri
ve melanom ï¿½ok say&#305;da metastaz yapar. Bazen kontrasts&#305;z BTï¿½de
lezyonlarda kanama gï¿½zlenebilir. En s&#305;k kanayan metastazlar melanom,
koryokarsinom, akci&#287;er, renal ve surrenal kanserlerine aittir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Ay&#305;r&#305;c&#305;
tan&#305;:<b> </b></span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Metastatik hastal&#305;&#287;&#305;n
ay&#305;r&#305;c&#305; tan&#305;s&#305;nda primer beyin tï¿½mï¿½rleri, infeksiyï¿½z
lezyonlar, a&#351;a&#287;&#305;da sï¿½zï¿½ edilecek olan paraneoplastik sendromlar,
baz&#305; durumlarda demiyelinizan hastal&#305;k akla gelmelidir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tedavi:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Akut iyilik hali
sa&#287;lanmas&#305; iï¿½in kortikosteroidler kullan&#305;labilir. Standart
olarak gï¿½nde 16 mg deksametazon ile ba&#351;lanabilir, etki sa&#287;lanmazsa 48
saatte bir doz artt&#305;r&#305;larak 100 mg/gï¿½n dozuna kadar
ï¿½&#305;k&#305;labilir. Ancak ï¿½ok uzun kullan&#305;mda steroidlerin bilinen
sak&#305;ncalar&#305; gï¿½ndeme gelecektir. Kontrastl&#305; MRG ile
gï¿½sterilmi&#351; tek bir lezyon varsa, primer tï¿½mï¿½r de iyi durumdaysa,
metastaz&#305;n rezeksiyonu dï¿½&#351;ï¿½nï¿½lmelidir. Cerrahi giri&#351;imin
ard&#305;ndan da radyoterapi yap&#305;l&#305;r. Sistemik kemoterapinin
baz&#305; durumlar haricinde serebral metastazlara pek etkili
olmad&#305;&#287;&#305; dï¿½&#351;ï¿½nï¿½lmektedir. Cerrahi giri&#351;im
yap&#305;lamayan ya da multipl metastazl&#305; hastalarda sadece radyoterapi
uygulanabilir. Radyoterapinin 48-72 saat ï¿½ncesinde 16 mg deksametazon veya
e&#351;de&#287;erinin verilmesi akut radyoterapi yan etkilerini ï¿½nlemek
aï¿½&#305;s&#305;ndan yararl&#305;d&#305;r. Tedaviye ra&#287;men metastatik beyin
tï¿½mï¿½rlerinin prognozu kï¿½tï¿½dï¿½r. Ortalama sa&#287;kal&#305;m 6 ay
civar&#305;ndad&#305;r. Ancak lenfoma, baz&#305; meme kanserleri,
koryokarsinom, testis kanseri gibi radyasyona duyarl&#305; tï¿½mï¿½rlerde
sa&#287;kal&#305;m daha uzun olabilir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:13.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Spinal Metastaz</span></b><span lang=TR style='font-size:13.0pt;font-family:
Tahoma;mso-ansi-language:TR'> </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kanserli
hastalarda omurili&#287;i ilgilendiren ï¿½ï¿½ tip metastatik lezyon vard&#305;r. En
s&#305;k gï¿½rï¿½len epidural lezyonlard&#305;r. Bunlar&#305;n ï¿½o&#287;unlu&#287;u
omurlardaki kemik metastazlar&#305;ndan kaynaklan&#305;r. Ayr&#305;ca
paravertebral yap&#305;lardan ve epidural bo&#351;lukta yer alan metastatik
lezyonlardan da kaynaklanabilir. Bunun d&#305;&#351;&#305;nda tek bir kitle
halinde veya leptomeningial yay&#305;l&#305;m &#351;eklinde intradural
ekstramedï¿½ller yerle&#351;imli ve/veya intramedï¿½ller yerle&#351;imli
metastazlar da gï¿½rï¿½lebilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidural
metastaz:</span></i></b><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Vertebralar,
kemik metastaz&#305;na yol aï¿½an kanserlerde % 70ï¿½e varan oranlarda, en ï¿½ok
tutulan bï¿½lgelerdir. ï¿½o&#287;unlu&#287;u a&#287;r&#305; d&#305;&#351;&#305;nda
asemptomatik kal&#305;r. Bu a&#287;r&#305;, lokal ve &#351;iddetlidir.
Perkï¿½syonla hassasiyet saptan&#305;r. Yakla&#351;&#305;k ï¿½ï¿½te birlik bï¿½lï¿½mï¿½
epidural bas&#305;ya yol aï¿½abilir. Nï¿½rolojik bulgu veren spinal epidural
metastazlar&#305;n yakla&#351;&#305;k % 25ï¿½i meme, % 15ï¿½i akci&#287;er, % 10ï¿½u
prostat kanserine, % 10ï¿½u da lenforetikï¿½ler sistem tï¿½mï¿½rlerine aittir.
Yakla&#351;&#305;k % 10-15ï¿½inde primer bï¿½lge belirlenemeyebilir. En s&#305;k
dorsal vertebralarda metastaz gï¿½rï¿½lï¿½r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidural metastazlar
ba&#351;l&#305;ca ï¿½ï¿½ mekanizma ile belirti verir. 1) erken dï¿½nemde bas&#305;ya
ba&#287;l&#305; ak maddede ï¿½dem ve aksonal &#351;i&#351;me gï¿½rï¿½lï¿½r, bu dï¿½nemde
bas&#305;n&#305;n ortadan kald&#305;r&#305;lmas&#305; ile normal i&#351;lev
kazan&#305;labilir; 2) ï¿½zellikle ï¿½n ve arkadan bas&#305;da spinal
damarlar&#305;n s&#305;k&#305;&#351;mas&#305; ile medulla spinalis
infarkt&#305; geli&#351;ir; 3) bas&#305;ya ba&#287;l&#305; vazojenik ï¿½dem
geli&#351;ir, bu durum steroidlere cevapl&#305;d&#305;r. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nï¿½rolojik
aciller kapsam&#305;nda de&#287;erlendirilmesi gereken bu klinik tabloda</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>, a&#287;r&#305; ortaya
ï¿½&#305;kan ilk bulgudur. Bï¿½lgesel veya radikï¿½ler nitelikte olan a&#287;r&#305;,
zaman iï¿½ersinde oldukï¿½a &#351;iddetli bir nitelik kazan&#305;r. Klinik
ba&#287;lamda; hasta yatar durumdayken &#351;iddetlenir, ki&#351;i otururken
daha rahatt&#305;r. Ard&#305;ndan parestezi gibi duysal yak&#305;nmalar ve
h&#305;zl&#305;ca, tutulan miyotoma ï¿½zgï¿½, kas zaaf&#305; geli&#351;ir.
Ayr&#305;ca etkilenen bï¿½lgeye gï¿½re seviye gï¿½steren tam veya k&#305;smi medï¿½ller
sendrom bulgular&#305; bulunabilir (Bak&#305;n&#305;z:Sinir Sistemi
Semiyolojisi). Klasik medï¿½ller sendrom bulgular&#305; d&#305;&#351;&#305;nda
nadiren Lhermitte belirtisi, psï¿½doklodikasyon, papilï¿½dem, spinal miyokloniler
ve ï¿½ok ender olarak ï¿½moving toesï¿½ gï¿½rï¿½lebilir. Epidural metastaz&#305;n
ay&#305;r&#305;c&#305; tan&#305;s&#305;nda epidural kanama, epidural abse, disk
f&#305;t&#305;kla&#351;mas&#305; ve di&#287;er epidural kitleler akla
gelmelidir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;ntradural
ve intramedï¿½ller metastaz:</span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> Dura iï¿½erisindeki metastazlar metastatik spinal tï¿½mï¿½rlerin
en az&#305;n&#305;, yakla&#351;&#305;k % 5 kadar&#305;n&#305; olu&#351;turur.
&#304;ntradural ekstramedï¿½ller metastazlar bir sonraki leptomeningial metastaz
ba&#351;l&#305;&#287;&#305; alt&#305;nda incelenecektir. Bu tï¿½r metastazlar
nadiren intradural bir kitle olu&#351;turarak etki edebilirler.
&#304;ntramedï¿½ller metastazlar ise daha ï¿½ok hematojen yolla olur. Bazen de
leptomeningial tï¿½mï¿½r omurili&#287;i infiltre eder. Sonuï¿½ta oldukï¿½a nadir bir
durumdur. &#304;ntramedï¿½ller metastaz&#305;n en s&#305;k nedenleri;
akci&#287;er tï¿½mï¿½rleri (yakla&#351;&#305;k % 50), meme kanseri ve Hodgkin,
Hodgkin-d&#305;&#351;&#305; lenfomalard&#305;r. Klini&#287;i, a&#287;r&#305;
daha geri planda olmak ï¿½zere epidural bas&#305; gibidir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nï¿½roradyoloji:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Gerek epidural
bas&#305;, gerekse intramedï¿½ler metastaz ku&#351;kusu olan durumlarda en uygun
inceleme yï¿½ntemi kontrasts&#305;z ve kontrastl&#305; spinal MRGï¿½dir. Kemik
metastaz&#305;na ba&#287;l&#305; epidural bas&#305;larda direkt radyografiler
bile olgular&#305;n % 75ï¿½inden fazlas&#305;nda sorumlu lezyonu gï¿½sterebilir. Bu
durumda kemik sintigrafisi yararl&#305; olabilir. Bas&#305;n&#305;n dï¿½zeyini
belirlemek iï¿½in ï¿½nceki y&#305;llarda miyelografi ve intratekal kontrastl&#305;
BT ï¿½ekilirdi. Ancak, MRG sonras&#305; bu yï¿½ntemler nadiren
uygulanmaktad&#305;r. MRG pek ï¿½ok farkl&#305; olas&#305;l&#305;&#287;&#305;n
ay&#305;rdedilmesinde yararl&#305;d&#305;r. ï¿½zellikle intramedï¿½ller
metastazlar&#305;n gï¿½rï¿½lmesini sa&#287;lar. &#304;ntramedï¿½ller metastazlar
MRGï¿½de solid, s&#305;n&#305;rlar&#305; belirgin kitle &#351;eklinde gï¿½rï¿½lï¿½r.
Genellikle T1ï¿½de hipointens, T2ï¿½de hiperintenstir ve yo&#287;un kontrast
tutulumu gï¿½sterir. &#304;ntramedï¿½ller metastazlar&#305;n radyolojik
ay&#305;r&#305;c&#305; tan&#305;s&#305;na primer medï¿½ller tï¿½mï¿½rler, radyasyon
miyelopatisi, vaskï¿½ler omurilik hastal&#305;&#287;&#305;, paraneoplastik
miyelopati ve demiyelinizan miyelopati girebilir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tedavi:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Epidural metastaz
bas&#305;s&#305; ï¿½ok acil bir durumdur. Bugï¿½n yayg&#305;n kabul gï¿½ren tedavi
&#351;ekli acil radyoterapi veya cerrahi dekompresyon sonras&#305;nda
radyoterapi yap&#305;lmas&#305;d&#305;r. Ancak epidural bas&#305; saptan&#305;r
saptanmaz di&#287;er tedavi seï¿½enekleri gerï¿½ekle&#351;tirilene kadar beklemeden
hemen yï¿½ksek doz steroid (100 mg deksametazon veya 1000 mg metil prednizolon)
yap&#305;lmas&#305; gereklidir. &#304;ntramedï¿½ller metastazlar&#305;n
tedavisinde genellikle steroidler ve radyoterapi yer al&#305;r. Metastazektomi
ï¿½ok nadir durumlarda dï¿½&#351;ï¿½nï¿½lebilir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Leptomeningial
Metastaz</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> : Meninkslerin malign hï¿½creler taraf&#305;ndan infiltre edilmesi
leptomeningial metastaz olarak adland&#305;r&#305;l&#305;r. Bu hï¿½creler lï¿½semik
hï¿½crelerse bu duruma meningial lï¿½semi (veya lï¿½semik menenjit), kanser hï¿½creleri
ise meningial karsinomatoz (veya karsinomatoz menenjit) ad&#305; verilir.
Kanserli hastalarda leptomeningial metastaz s&#305;kl&#305;&#287;&#305; tam
olarak bilinmemekle beraber primer neoplazinin niteli&#287;ine gï¿½re
de&#287;i&#351;kenlik gï¿½sterir. Solid tï¿½mï¿½rlï¿½ hastalar&#305;n
yakla&#351;&#305;k %5ï¿½inde gï¿½rï¿½lï¿½rken hematolojik neoplazili hastalarda
(lï¿½semi, lenfoma) bu oran %5-15 aras&#305;nda olabilir. Ancak, bir otopsi
ï¿½al&#305;&#351;mas&#305;nda nï¿½rolojik bulgu veren kanserli olgular&#305;n
%19ï¿½unda saptanm&#305;&#351; olmas&#305;, muhtemelen hastalar&#305;n bir
k&#305;sm&#305;nda gï¿½zden kaï¿½abildi&#287;ini dï¿½&#351;ï¿½ndï¿½rmektedir.
Leptomeningial metastaz yapabilen di&#287;er tï¿½mï¿½rler meme kanseri, kï¿½ï¿½ï¿½k
hï¿½creli akci&#287;er kanseri, melanom ile non-Hodgkin lenfoma, akut lenfositik
ve non-lenfositik lï¿½semi gibi hematolojik tï¿½mï¿½rlerdir. Leptomeningial metastaz
genellikle geï¿½ dï¿½nemde, yayg&#305;n hastal&#305;kla birlikte ortaya ï¿½&#305;kar.
ï¿½ok daha seyrek olarak birkaï¿½ y&#305;l&#305; bulan hastal&#305;ks&#305;z
dï¿½nemin ard&#305;ndan ortaya ï¿½&#305;kabilir. Bazen de sistemik kanserin ilk
belirtisini olu&#351;turdu&#287;undan klinik tan&#305;y&#305; koymak son derece
ï¿½nemlidir. Primeri bilinmeyen karsinomatoz menenjit, olgular&#305;n
yakla&#351;&#305;k %5ï¿½ini olu&#351;turmaktad&#305;r. Tï¿½mï¿½rlerde
sa&#287;kal&#305;m&#305;n&#305;n artmas&#305; ile orant&#305;l&#305; olarak
insidensi artar. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Leptomeningial
metastazlar genellikle multifokal belirti ve bulgular verir. BOS
dolan&#305;m&#305;n&#305; bozarak kafa iï¿½i bas&#305;nï¿½ art&#305;&#351;&#305;
sendromuna yol aï¿½ar; damarlar&#305;n parenkim iï¿½ine girdi&#287;i Virchow-Robin
aral&#305;klar&#305;n&#305; izleyerek parenkim invazyonu yapar ve epileptik
nï¿½betlere veya genel bir ensefalopati tablosuna yol aï¿½ar; yine Virchow-Robin
aral&#305;klar&#305;na yay&#305;lm&#305;&#351; tï¿½mï¿½r hï¿½creleri burada yer alan
damarlardaki ak&#305;m&#305; bozarak iskemiye neden olur. Bï¿½tï¿½n bunlara
ba&#287;l&#305; olarak hastalarda ï¿½ï¿½ ana grupta belirtiler ortaya
ï¿½&#305;kabilir: serebral hemisferik tutuluma ba&#287;l&#305;
ba&#351;a&#287;r&#305;s&#305; olabilir, mental de&#287;i&#351;iklik
gï¿½rï¿½lebilir, bulant&#305;-kusma olur, dengesizlik ve yï¿½rï¿½me gï¿½ï¿½lï¿½&#287;ï¿½
olabilir. Diabetes insipidus gï¿½rï¿½lebilir. &#304;kinci grup bulgu multipl
kranyal sinir tutulumuna ait bulgulard&#305;r; ï¿½ï¿½ï¿½ncï¿½ grupta da poliradikï¿½ler
tutuluma ba&#287;l&#305; radikï¿½ler a&#287;r&#305; ve asimetrik refleks
kayb&#305; say&#305;labilir. Seyrek olarak meningial iritasyon bulgular&#305;
saptanabilir. ï¿½zetle; merkezi sinir sistemine ili&#351;kin farkl&#305;, birkaï¿½
anatomik lokalizasyon bulgusu saptanan hastalarda bu tan&#305;
olas&#305;l&#305;&#287;&#305; kuvvetle dï¿½&#351;ï¿½nï¿½lmeli ve acilen tan&#305;
koydurucu incelemeler yap&#305;lmal&#305;d&#305;r. ï¿½nceden de sï¿½zï¿½
edildi&#287;i gibi, sistemik kanseri bilinmeyen bir hasta meningial tutuluma
ba&#287;l&#305; nï¿½rolojik tablo nedeniyle ï¿½ncelikle nï¿½rolo&#287;a
ba&#351;vuracakt&#305;r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tan&#305;:</span></i><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Meningial tutulum
tan&#305;s&#305; BOS incelemesinde malign hï¿½cre gï¿½rï¿½lmesi ile konur. Ancak
nï¿½rolojik bulgular&#305; olan bir kanser hastas&#305;nda BOS incelemesinden
ï¿½nce yer kaplayan bir kitleyi d&#305;&#351;lamak iï¿½in kranyal ve spinal MRG
yap&#305;lmal&#305;d&#305;r. MRG s&#305;ras&#305;nda kontrast madde verilirse
meninkslerde da&#287;&#305;n&#305;k lineer veya nodï¿½ler kontrast tutulumu gï¿½zlenebilir.
Yer kaplay&#305;c&#305; kitleyi d&#305;&#351;laman&#305;n yan&#305; s&#305;ra,
bazen lomber ponksiyon sonras&#305;nda meningial kontrast tutulumu
gï¿½rï¿½lebilece&#287;inden, BOS incelemesinin MR sonras&#305;nda
yap&#305;lmas&#305; daha do&#287;ru olacakt&#305;r. Gerekli BOS incelemeleri
aras&#305;nda bas&#305;nï¿½ ï¿½lï¿½ï¿½mï¿½, hï¿½cre say&#305;m&#305;, protein ve &#351;eker
dï¿½zeyi ï¿½lï¿½ï¿½mï¿½, sitolojik inceleme yer al&#305;r. &#304;nfeksiyon ku&#351;kusu
varsa buna yï¿½nelik incelemeler de yap&#305;lmal&#305;d&#305;r. BOSï¿½ta
genellikle birkaï¿½ hï¿½creden birkaï¿½ yï¿½z hï¿½creye kadar de&#287;i&#351;ebilen bir
lenfositik pleositozun yan&#305; s&#305;ra malign hï¿½creler de gï¿½rï¿½lï¿½r. Protein
dï¿½zeyi artm&#305;&#351;t&#305;r, immunglobulin dï¿½zeyleri de artabilir.
&#304;ntratekal immunglobulin sentezini gï¿½steren oligoklonal bantlar
saptanabilir. Buna kar&#351;&#305;n, s&#305;k gï¿½rï¿½lmese de BOS &#351;ekerinin
azalmas&#305; ï¿½nemli bir bulgudur. Leptomeningial metastaz tan&#305;s&#305;nda BOS
incelemesinin en ï¿½nemli k&#305;sm&#305; sitolojidir. Sitoloji
laboratuvar&#305;na en az 4 ml BOS gï¿½nderilmelidir. BOSï¿½un bekletilmeden
gï¿½nderilmesi ï¿½ok ï¿½nemlidir. ï¿½ok ï¿½nerilmemekle birlikte, laboratuvara hemen
ula&#351;mayacaksa BOS al&#305;n&#305;r al&#305;nmaz e&#351;it miktarda saf
alkol eklenerek fikse edilmesi denenebilir. &#304;lk BOS incelemesinde pozitif
sitolojik sonuï¿½ elde etme &#351;ans&#305; % 50 civar&#305;ndad&#305;r; bu oran
ikinci incelemede % 80ï¿½i bulur. E&#287;er ilk al&#305;nan BOSï¿½ta malign hï¿½cre
saptanamazsa, inceleme bir kere daha yinelenmelidir. Hala negatifse, ancak
klinik ku&#351;ku gï¿½ï¿½lï¿½yse ï¿½ï¿½ï¿½ncï¿½ kez de al&#305;nabilir. Mï¿½mkï¿½nse rutin
sitolojik incelemenin yan&#305; s&#305;ra immunhistokimyasal
ï¿½al&#305;&#351;malar ve yï¿½zey belirteci ï¿½al&#305;&#351;malar&#305; da
yap&#305;lmal&#305;d&#305;r. Bunlar&#305;n d&#305;&#351;&#305;nda BOSï¿½ta tï¿½mï¿½r
belirteï¿½leri (karsinoembriyojenik antijen, alfa-fetoprotein, beta-koryonik
gonadotropin) kandaki konsantrasyonlardan ï¿½ok daha yï¿½ksek konsantrasyonda
bulunursa ï¿½zellikle primer tï¿½mï¿½r hakk&#305;nda ipucu vermesi
bak&#305;m&#305;ndan yararl&#305; olabilir. Baz&#305; durumlarda, ï¿½zellikle
kauda ekuina sendromu sï¿½z konusu ise, BOS al&#305;n&#305;rken intratekal
kontrast madde verilerek miyelografi yap&#305;labilir. Kï¿½k
k&#305;l&#305;flar&#305; iï¿½inde dolum defektleri gï¿½rï¿½lmesi tan&#305;y&#305;
kuvvetle destekler. Ayr&#305;ca radyoizotop BOS ak&#305;m
ï¿½al&#305;&#351;malar&#305; da BOS dolan&#305;m&#305;n&#305;n bozuldu&#287;u
bï¿½lgeleri gï¿½stermek aï¿½&#305;s&#305;ndan yararl&#305;d&#305;r. Klinik olarak
ay&#305;r&#305;c&#305; tan&#305;da en ï¿½nemli grup MSS
infeksiyonlar&#305;d&#305;r. &#304;nfeksiyonda en ï¿½nemli ay&#305;r&#305;c&#305;
ï¿½zellik ate&#351; ve ense sertli&#287;i gibi bulgular&#305;n ï¿½n planda
olmas&#305;, fokal nï¿½rolojik bulgular&#305;n pek gï¿½rï¿½lmemesidir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tedavi:</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Leptomeningial
metastaz tedavisinde radyoterapi ile birlikte kemoterapi uygulan&#305;r.
Radyoterapinin semptomatik bï¿½lgelere s&#305;n&#305;rl&#305; tutulmas&#305;
toksisite aï¿½&#305;s&#305;ndan daha olumlu olabilir. Kemoterapinin ne yolla
verilece&#287;i halen tart&#305;&#351;mal&#305; ise de, intratekal uygulama
s&#305;kï¿½a tercih edilir. Ancak ne &#351;ekilde tedavi edilirse edilsin, solid
tï¿½mï¿½re ba&#287;l&#305; leptomeningial metastazl&#305; hastalarda prognoz
kï¿½tï¿½dï¿½r. Hastalar tedavi edilmedi&#287;inde birkaï¿½ haftal&#305;k
sa&#287;kal&#305;m sï¿½z konusudur. Tedavi yerle&#351;mi&#351; nï¿½rolojik
defisitleri dï¿½zeltmese bile hastal&#305;k progresyonunu yava&#351;latabilir
veya durdurabilir; medyan sa&#287;kal&#305;m&#305;n tedavi ile birkaï¿½ aya
ï¿½&#305;kmas&#305; mï¿½mkï¿½ndï¿½r. Ayr&#305;ca BOS dolan&#305;m bozuklu&#287;u varsa
ventrikï¿½loperitoneal &#351;ant tak&#305;labilir. Solid tï¿½mï¿½re ba&#287;l&#305;
leptomeningial metastaz&#305; olan bï¿½tï¿½n hastalar agresif tedavi almak zorunda
de&#287;ildir. Ya&#351;am beklentisi 3 aydan k&#305;sa olan, genel durum
bozuklu&#287;u bulunan (Karnofsky performans skalas&#305; &lt;%60) ve MSS tï¿½mï¿½r
yï¿½kï¿½ ï¿½ok fazla olan hastalarda sadece destek tedavisi yapmak yeterli
olacakt&#305;r. Hematolojik neoplazilerde ise prognoz ï¿½ok daha iyidir. Lï¿½semi hastalar&#305;nda
% 75 oran&#305;nda stabilizasyon ve dï¿½zelme gï¿½rï¿½lï¿½r. Lenfomada da prognoz&nbsp;
solid tï¿½mï¿½rlere oranla ï¿½ok daha iyidir. Bu nedenle bu hastalar
&#305;srarl&#305; bir &#351;ekilde tedavi edilmelidir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><a name="Metastaz_d&#305;&#351;&#305;"></a><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>Metastaz
D&#305;&#351;&#305; Etkiler</span></b><span lang=TR style='font-size:14.0pt;
font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nï¿½rolojik
bulgu gï¿½steren kanserli hastalar&#305;n yar&#305;s&#305;nda nï¿½rolojik tabloya
neden olan herhangi bir metastaz veya tï¿½mï¿½r yay&#305;l&#305;m&#305; saptanmaz.
Bu durumda ï¿½ok farkl&#305; nedenler nï¿½rolojik tablodan sorumlu olabilir. Bu
nedenler a&#351;a&#287;&#305;da s&#305;ralanm&#305;&#351;t&#305;r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:13.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&#304;nfeksiyï¿½z, Metabolik, Vaskï¿½ler Etkiler </span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;nfeksiyonlar:
</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kanserli
hastalarda hem tï¿½mï¿½re ba&#287;l&#305; geli&#351;en immunsupresyon, hem de
tedaviye ba&#287;l&#305; kemik ili&#287;i bask&#305;lanmas&#305; sonucu
infeksiyonlar s&#305;k gï¿½rï¿½lï¿½r. Bunlar aras&#305;nda MSS infeksiyonlar&#305; da
yer al&#305;r. Bu konunun ayr&#305;nt&#305;lar&#305; <a
href="http://www.itfnoroloji.org/infeksiyon/infection.htm">Sinir Sistemi
&#304;nfeksiyonlar&#305;</a> konusunda anlat&#305;laca&#287;&#305;ndan burada
ï¿½ok k&#305;saca de&#287;inilecektir. T-lenfosit ve mononï¿½kleer fagosit sistemi
bozuk olan hastalarda nï¿½trofil i&#351;levleri veya total lï¿½kosit
say&#305;s&#305; normal olsa bile; <i>Listeria </i>ve <i>Nocardia</i> gibi
bakteriyel infeksiyonlar, ï¿½zellikle kriptokok gibi mantar, herpes zoster,
herpes simpleks ve sitomegalovirus infeksiyonlar&#305; ba&#351;ta olmak ï¿½zere
virus infeksiyonlar&#305;, toksoplazmoz gibi parazitozlar ve progresif
multifokal lï¿½koensefalopati tablosu s&#305;k gï¿½rï¿½lï¿½r. Granï¿½lositopenisi veya
nï¿½trofil i&#351;lev bozuklu&#287;u olan hastalarda ï¿½zellikle bakteriyel
infeksiyonlara e&#287;ilim artar. Nï¿½trofil mutlak say&#305;s&#305; 1000/mm<sup>3</sup>ï¿½ï¿½n
alt&#305;nda olan hastalarda enterik basiller (<i>Psï¿½domonas</i> grubu, <i>E.
coli</i>, <i>Klebsiella</i>), streptokok, stafilokoklar ile birlikte <i>Listeria</i>
infeksiyonlar&#305;na ve kandida, aspergillus ve mukormikoz gibi mantar
infeksiyonlar&#305;na e&#287;ilim artar. B-lenfosit yetersizli&#287;i nadir
gï¿½rï¿½lï¿½r. Bu durumda <i>S. pneumoniae</i>, <i>H. influenza</i>e ve <i>N.
meningitidis</i> infeksiyonlar&#305;na e&#287;ilim artar. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Metabolik
etkiler:</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Kanserli hastalarda pek ï¿½ok nedenle nutrisyonel ve metabolik bozukluklar
meydana gelebilir. ï¿½ncelikle kanserin tuttu&#287;u organ&#305;n
i&#351;levlerini bozmas&#305; ile o organ sistemine ait yetersizlikler
olabilir; bunlar&#305;n aras&#305;nda hipoksi, karaci&#287;er ve bï¿½brek
yetersizliklerine ba&#287;l&#305; ensefalopatiler say&#305;labilir. Varolan
metabolik bozuklu&#287;a ba&#287;l&#305; olarak metabolik ensefalopatiler
geli&#351;ebilir. <i>Metabolik ensefalopati</i> deyimi, bozulmu&#351; serebral
metabolizma sonucu olu&#351;an davran&#305;&#351; de&#287;i&#351;ikliklerini
iï¿½erir. Akut ya da subakut olarak geli&#351;en bu tablonun klinik
bulgular&#305;; konfï¿½zyon, dï¿½&#351;ï¿½nce kusurlar&#305;, davran&#305;&#351;
bozukluklar&#305;, bilinï¿½ dï¿½zeyinde de&#287;i&#351;imler ve bazen de anormal
motor aktiviteler &#351;eklinde ï¿½zetlenebilir. ï¿½zetle; huzursuzluk, letarji,
emosyonel labilite, uyuklama ya da uykusuzluk gibi bulgulara tremor,
miyokloniler ve asteriksis gibi istemsiz hareketler e&#351;lik etti&#287;inde
bu tan&#305; olas&#305;l&#305;&#287;&#305; akla gelmelidir. Bu s&#305;kï¿½a
kar&#351;&#305;la&#351;&#305;lan klinik tablo altta yatan nedene yï¿½nelik tedavi
ile geriye dï¿½ner. EEGï¿½de yayg&#305;n yava&#351; dalga varl&#305;&#287;&#305;
saptan&#305;r. Ayr&#305;ca bu hastalarda s&#305;v&#305;-elektrolit dengesindeki
bozukluklar, ï¿½zellikle meme kanserli hastalarda hiperkalsemi s&#305;kï¿½a
gï¿½rï¿½lï¿½r. Kanserli hastalarda beslenme bozukluklar&#305; ve ka&#351;eksi de
oldukï¿½a s&#305;kt&#305;r. Beslenme bozukluklar&#305; aras&#305;nda en s&#305;k
gï¿½rï¿½lenler tiamin eksikli&#287;ine ba&#287;l&#305; <i>Wernicke-Korsakoff
sendromu</i>, B12 vitamini eksikli&#287;i ve niasin eksikli&#287;ine
ba&#287;l&#305; <i>pellegra</i> say&#305;labilir. Bu sonuncusu baz&#305;
kanserlerle gï¿½rï¿½len ve kanserin salg&#305;lad&#305;&#287;&#305; baz&#305;
peptidlere ba&#287;l&#305; diyare ataklar&#305;na yol aï¿½an karsinoid sendromda
s&#305;kt&#305;r. Metabolik bozukluklarla ilgili daha ayr&#305;nt&#305;l&#305;
bilgi<a href="http://www.itfnoroloji.org/metabolik/metobolik.htm"><span
style='color:windowtext;text-decoration:none;text-underline:none'> ilgili
bï¿½lï¿½mlerde</span></a> bulunabilir (Bak&#305;n&#305;z: <u><span
style='color:#0070C0'><a href="../metabolik/metobolik.htm">Metabolik
Ensefalopati</a></span></u> ve <u><span style='color:#0070C0'><a
href="../beslenme/beslenme.htm">Sinir sisteminin Nutrisyonel
Hastal&#305;klar&#305;</a></span></u>). </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Vaskï¿½ler
etkiler:</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Sistemik arteroskleroz oran&#305; genel popï¿½lasyona oranla kanserli
hastalarda daha dï¿½&#351;ï¿½k olmas&#305;na kar&#351;&#305;n, gï¿½rï¿½lme
s&#305;kl&#305;&#287;&#305; aï¿½&#305;s&#305;ndan serebrovaskï¿½ler komplikasyonlar
metastatik komplikasyondan sonra ikinci s&#305;rada yer al&#305;rlar. Kanserli
hastalarda kanay&#305;c&#305; ve t&#305;kay&#305;c&#305; serebrovaskï¿½ler
olaylar yakla&#351;&#305;k e&#351;it oranlarda gï¿½rï¿½lï¿½r. Kanay&#305;c&#305;
olaylar intraserebral kanamalar, kranyal ve spinal subdural ve epidural
kanamalar ve nadiren subaraknoid kanama &#351;eklinde kar&#351;&#305;m&#305;za
ï¿½&#305;kabilir. Kanay&#305;c&#305; olaylar&#305;n alt&#305;nda
s&#305;kl&#305;kla koagï¿½lasyon bozukluklar&#305; bulunur. Kemik ili&#287;inin
tï¿½mï¿½r infiltrasyonuna veya ilaï¿½larla bask&#305;lanmas&#305;na ba&#287;l&#305;
trombositopeni, trombosit i&#351;lev bozukluklar&#305;, karaci&#287;er
yetersizli&#287;ine ba&#287;l&#305; K vitamini eksiklikleri kanserli hastalarda
s&#305;k gï¿½rï¿½len kanama nedenleridir. Trombositopenili hastalarda lomber
ponksiyon yap&#305;lmas&#305; gerekiyorsa ï¿½ncesinde trombosit suspansiyonu
verilerek kanda trombosit say&#305;s&#305;n&#305;n 20 000/ mm<sup>3</sup>
dï¿½zeyinin ï¿½zerine ï¿½&#305;kar&#305;lmas&#305; gerekir, ayr&#305;ca ince
i&#287;ne ile (no. 20 veya 22) ve ï¿½ok dikkatli bir &#351;ekilde ponksiyon
yap&#305;lmal&#305;d&#305;r. Aksi halde spinal subdural veya epidural kanama
geli&#351;ebilir. Bazen tï¿½mï¿½rï¿½n tï¿½mï¿½r veya metastazlar&#305;n&#305;n iï¿½ine kanama
da gï¿½rï¿½lebilir. En s&#305;k kanayan beyin metastazlar&#305; melanom,
koryokarsinom, akci&#287;er, renal ve sï¿½rrenal kanserlerine aittir. Kanserli
hastalarda gï¿½rï¿½lebilen iskemik serebrovaskï¿½ler olaylar&#305;n
yakla&#351;&#305;k ï¿½ï¿½te birinin alt&#305;nda klasik aterosklerotik damar
darl&#305;klar&#305; bulunur. Geri kalan ï¿½o&#287;unlu&#287;unda farkl&#305; nedenler
sï¿½z konusudur. Bunlar aras&#305;nda disemine intravaskï¿½ler koagï¿½lasyon (DIC),
non-bakteriyel trombotik endokardit, septik emboli, tï¿½mï¿½r embolisi, tï¿½mï¿½r
bas&#305;s&#305; ile arter t&#305;kanmas&#305;n&#305;n yan&#305; s&#305;ra
meme, mide, akci&#287;er kanserleri ve lenfomada gï¿½rï¿½lebilen trombotik
mikroanjiyopati ile intravaskï¿½ler lenfoma say&#305;labilir. Kanserli hastalarda
yayg&#305;n (disemine) intravaskï¿½ler koagï¿½lasyon t&#305;kay&#305;c&#305;,
trombotik vaskï¿½ler hastal&#305;klar iï¿½erisinde ilk s&#305;ray&#305; al&#305;r.
Her tï¿½rlï¿½ malinitede gï¿½rï¿½lmekle birlikte lï¿½koz ve lenfomalarda daha
s&#305;kt&#305;r. Genelde ï¿½lï¿½mle sonlanan bu klinik tablo; akut geli&#351;en
ensefalopati, buna eklenen fokal ya da jeneralize konvï¿½lsiyonlar ile
karakterizedir. Fokal nï¿½rolojik bulgu varsa hafiftir. Serebral venï¿½z
oklï¿½zyonlar ise her tï¿½rlï¿½ sistemik kanserde gï¿½rï¿½lmekle birlikte lï¿½koz ve
lenfomalarda s&#305;kt&#305;r. &#350;iddetli ba&#351;
a&#287;r&#305;s&#305;n&#305; izleyen konvï¿½lsiyonlarda bu tan&#305; akla
gelmelidir. Yine baz&#305; kanserlerin (jinekolojik, meme, akci&#287;er
kanserleri ve hematolojik neoplaziler) salg&#305;lad&#305;&#287;&#305;
pro-koagulan maddeler ile baz&#305; kanserlerde de (prostat, meme) dural
metastazlar nedeni ile majï¿½r venï¿½z sinï¿½slerde t&#305;kanma gï¿½rï¿½lebilir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:13.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Tedavi Komplikasyonlar&#305;</span></b><span lang=TR style='font-size:13.0pt;
font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kemoterapi
Yan Etkileri </span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kanser
tedavisinde kullan&#305;lan kemoterapï¿½tiklere ba&#287;l&#305; gï¿½rï¿½lebilen
nï¿½rolojik yan etkiler <b>Tablo 5</b>ï¿½te s&#305;ralanm&#305;&#351;t&#305;r.
S&#305;k gï¿½rï¿½len baz&#305; ï¿½zel durumlar burada biraz daha
ayr&#305;nt&#305;l&#305; olarak ele al&#305;nacakt&#305;r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>Tablo 5. Nï¿½rotoksik etki gï¿½steren kemoterapï¿½tikler </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(Kaynak
3 ve 26ï¿½dan)) </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;background:#FFFFCC;mso-padding-alt:
 0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>Akut ensefalopati (delirium)</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=DE
  style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'>Metotreksat (intravenï¿½z veya intratekal),
  kortikosteroidler, sis-platin, vinkristin, asparaginaz, prokarbazin,
  5-florourasil, Ara-C, nitrozï¿½reler, siklosporin, interlï¿½kin-2, ifosfamid/
  mesna, interferonlar, tamoksifen, VP-16, PALA, bevasizumab, kapesitabine,
  etoposid, paklitaksel</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:TR'>Kronik
  ensefalopati (demansiyel sendrom)</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> <br>
  Metotreksat , BCNU, Ara-C, fludarabin</span><span lang=DE style='mso-ansi-language:
  DE'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gï¿½rme kayb&#305;</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'> </span><span lang=DE style='mso-ansi-language:
  DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'>Tamoksifen, galyum nitrat,
  nitrozï¿½reler, sis-platin </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:TR'>Serebellar
  bozukluk/ ataksi</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'> <br>
  5-florourasil, Ara-C, prokarbazin, vinkristin, siklosporin A </span><span
  lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:TR'>Aseptik
  menenjit</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'> <br>
  monoklonal antikorlar, OKT 3, Ara-C (intratekal), metotreksat (intratekal) </span><span
  lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;a&#287;r&#305;s&#305;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  Tamoksifen, temozolamid</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:TR'>Epileptik
  nï¿½bet</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <br>
  Metotreksat, etoposid, sis-platin, vinkristin, asparaginaz, nitrojen mustard,
  prokarbazin, BCNU, dakarbazin, busulfan, siklosporin, ifosfamid, paklitaksel,
  klorambusil</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR
  style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:TR'>Miyelopati
  (intratekal ajanlar)</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'> <br>
  Metotreksat, Ara-C, tiotepa </span><span lang=DE style='mso-ansi-language:
  DE'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>Periferik nï¿½ropati</span><span lang=DE
  style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Vinka alkaloidleri, sis-platin, prokarbazin, 5-azasitidin, etoposid,
  5-florourasil, Ara-C, taksol, suramin, mitotan, bortezomab, dosetaksel,
  oksaliplatin, teniposid, talidomid</span><span lang=DE style='mso-ansi-language:
  DE'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Periferik
nï¿½ropati:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Kemoterapiye ba&#287;l&#305; periferik nï¿½ropati genellikle distal-simetrik
bir polinï¿½ropatidir. Nadiren fokal nï¿½ropatiler gï¿½rï¿½lebilir. Suramin demiyelinizan,
duysal-motor nï¿½ropatiye yol aï¿½arken, vinkristin aksonal duysal-motor nï¿½ropatiye
yol aï¿½ar. Her ikisi de tedavinin kesilmesi ile bir miktar dï¿½zelebilir. Taksol
ve sis-platin ise saf duysal nï¿½ropatiye yol aï¿½ar. Sis-platin ile sadece
kal&#305;n lifler tutulurken, taksol ile ince lifler de tutulur. Arka kï¿½k
gangliyonundaki hasar&#305;n dï¿½zeyine ba&#287;l&#305; de&#287;i&#351;mekle
birlikte tedavinin kesilmesi ile dï¿½zelebilir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Metotreksat
toksisitesi:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Bir folik asit antagonisti olan metotreksat ile ili&#351;kili akut veya
kronik nï¿½rotoksisite oldukï¿½a iyi bilinir. En s&#305;k gï¿½rï¿½len metotreksat
toksisitesi <i>aseptik menenjit</i>tir. &#304;ntratekal metotreksat alan
hastalar&#305;n % 10ï¿½unda gï¿½rï¿½lï¿½r. Genellikle ilac&#305;n verilmesinden 2-4
saat sonra ba&#351;lar, 12-72 saat sï¿½rer. Daha nadir bir komplikasyon ilac&#305;n
intraventrikï¿½ler uygulanmas&#305;ndan sonra gï¿½rï¿½lebilen <i>akut ensefalopati</i>dir.
Bu durum bazen, ï¿½zellikle kranyal &#305;&#351;&#305;nlama sonras&#305;nda
yï¿½ksek doz intravenï¿½z metotreksat uygulamas&#305; ile de gï¿½rï¿½lebilir.
Genellikle 24-48 saat iï¿½inde ba&#351;layan ve kendili&#287;inden dï¿½zelen
konfï¿½zyon, uykuya e&#287;ilim ve nï¿½betlerle kendini gï¿½sterir. Yine yï¿½ksek doz
intravenï¿½z metotreksat sonras&#305;nda 5.-6. gï¿½nde gï¿½rï¿½len ve inme-benzeri
tablolarla kendini gï¿½steren <i>subakut bir ensefalopati </i>gï¿½rï¿½lebilir. Bu
durum da 1-2 gï¿½n iï¿½inde kendili&#287;inden dï¿½zelir. ï¿½ok nadir olarak intratekal
metotreksat tedavisinin bir komplikasyonu olarak <i>transvers miyelit</i>
gï¿½rï¿½lï¿½r. Genellikle intratekal injeksiyondan sonra ilk 48 saat iï¿½inde, nadiren
ilk 2 hafta iï¿½inde ortaya ï¿½&#305;kar. Dï¿½zelme de&#287;i&#351;kendir. Baz&#305;
olgular tam dï¿½zelirken, baz&#305;ar&#305;nda hiï¿½ dï¿½zelme gï¿½rï¿½lmeyebilir.
Metotreksat tedavisinin en ciddi yan etkilerinden biri <i>kronik
lï¿½koensefalopati</i>dir. Genellikle yineleyen yï¿½ksek doz intravenï¿½z veya
intratekal metotreksat tedavisinden aylar veya y&#305;llar sonra geli&#351;ir.
Ani ba&#351;layan veya yava&#351; geli&#351;en mental gerileme ve
davran&#305;&#351; de&#287;i&#351;iklikleri ortaya ï¿½&#305;kar. Seyir
de&#287;i&#351;kendir; bazen &#305;l&#305;ml&#305; bir demansiyel tablo olarak
stabilize olurken, baz&#305; durumlarda ilerleyici bir gidi&#351;le spastik
tetraparezi, nï¿½betler ve ï¿½lï¿½mle sonlanabilir. Yayg&#305;n miyelin
y&#305;k&#305;m&#305;na ba&#287;l&#305; olarak MRï¿½da yayg&#305;n ak madde
hiperintensitesi gï¿½rï¿½nï¿½r. Metotreksatla birlikte kranyal radyoterapi
uygulanm&#305;&#351; hastalarda lï¿½koensefalopati gï¿½rï¿½lme &#351;ans&#305; ve
&#351;iddeti daha fazlad&#305;r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Radyoterapi
Yan Etkileri:</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Radyoterapi uygulanan
MSS bï¿½lgesi ortaya ï¿½&#305;kacak yan etkiler aï¿½&#305;s&#305;ndan da
belirleyicidir. Sinir sistemine radyasyon toksisitesi zamansal olarak
genellikle ï¿½ï¿½ ana ba&#351;l&#305;k alt&#305;nda incelenebilir: 1. akut, 2.
erken-gecikmi&#351;, 3. geï¿½-gecikmi&#351; radyasyon toksisitesi. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>A. Radyasyon
Ensefalopatisi:</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>1. <i>Akut
ensefalopati:</i> Kafa iï¿½i bas&#305;nï¿½ art&#305;&#351;&#305;na yol
aï¿½m&#305;&#351; bï¿½yï¿½k tï¿½mï¿½rlerde bï¿½yï¿½k bir fraksiyon halinde (&gt;300 cGy)
radyoterapi uygulanmas&#305;ndan sonra ortaya ï¿½&#305;kar. ï¿½ncesinde steroid
verilmemesi riski artt&#305;r&#305;r. Tedaviden hemen sonra veya birkaï¿½ saat
iï¿½inde nï¿½rolojik tabloda kï¿½tï¿½le&#351;me, ba&#351;a&#287;r&#305;s&#305;,
bulant&#305;-kusma, uyan&#305;kl&#305;k kusuru ve ate&#351; geli&#351;ir;
genellikle kendine s&#305;n&#305;rl&#305; bir tablo olsa da nadiren ï¿½lï¿½mcï¿½l
olabilir. Bu durumun ï¿½nlenmesi iï¿½in radyoterapi fraksiyonlar&#305;n&#305;n 200
cGyï¿½in alt&#305;nda tutulmas&#305; ve 24-72 saat ï¿½ncesinden 16 mg/gï¿½n
deksametazon ba&#351;lanmas&#305; ï¿½nerilmektedir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>2. <i>Erken
gecikmi&#351; ensefalopati: </i>Gerek beyin tï¿½mï¿½rï¿½ nedeniyle gerekse
profilaktik olarak kranyal radyoterapi alan hastalarda radyoterapiden sonraki 2
hafta- 4 ay iï¿½inde ortaya ï¿½&#305;kar. Hastada ba&#351;a&#287;r&#305;s&#305;,
uykuya e&#287;ilim ba&#351;lar, eski nï¿½rolojik bulgular tekrar belirir ve
kï¿½tï¿½le&#351;ir. Bu durumu klinik ve radyolojik olarak primer tï¿½mï¿½rï¿½n nï¿½ksï¿½nden
ay&#305;rdetmek ï¿½ok zordur. BT ve MRGï¿½de kontrast tutan, etraf&#305; ï¿½demli bir
bï¿½lge gï¿½rï¿½lï¿½r. PET incelemesi ayr&#305;m&#305; sa&#287;layabilir. Bu tablonun
tï¿½mï¿½r nï¿½ksï¿½nden tek fark&#305;, hem klinik hem de radyolojik tablonun birkaï¿½
hafta iï¿½inde kendili&#287;inden dï¿½zelme gï¿½stermesidir. Steroidler bu dï¿½zelmeyi
h&#305;zland&#305;rabilir. Bu nedenle bï¿½yle hastalar steroid tedavisi
alt&#305;nda s&#305;k gï¿½rï¿½ntï¿½lemelerle izlenmelidir. Yap&#305;lm&#305;&#351;
histopatolojik incelemeler akson kayb&#305;n&#305;n geri planda oldu&#287;u
demiyelinizasyonu gï¿½sterir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>3. <i>Geï¿½
gecikmi&#351; ensefalopati:</i> Radyasyon nekrozu genellikle beyin tï¿½mï¿½rï¿½ veya
ba&#351;-boyun tï¿½mï¿½rleri nedeniyle yap&#305;lan kranyal radyoterapi
tamamland&#305;ktan sonraki 1-2 y&#305;l iï¿½inde ortaya ï¿½&#305;kar. BT ve MRGï¿½de
beyin tï¿½mï¿½rlï¿½lerde eski tï¿½mï¿½r bï¿½lgesinde, ba&#351;-boyun tï¿½mï¿½rlï¿½lerde de
&#305;&#351;&#305;nlanan alandaki beyin parenkiminde kontrast tutulumu ile
ï¿½evresel ï¿½dem gï¿½rï¿½lï¿½r. Bu durumun da klinik ve radyolojik olarak primer tï¿½mï¿½rï¿½n
nï¿½ksï¿½nden ay&#305;rdedilmesi ï¿½ok zordur. Yukar&#305;da sï¿½zedildi&#287;i gibi,
PET incelemesi veya MR spektroskopi ayr&#305;m&#305; sa&#287;layabilir.
Histolojik olarak radyasyon nekrozunun yukar&#305;da sï¿½zï¿½ geï¿½en kronik metotreksat
ensefalopatisinden ay&#305;rdedilmesi de gï¿½ï¿½tï¿½r. Kranyal radyoterapi
sonras&#305;nda radyonekroz s&#305;kl&#305;&#287;&#305; % 3-5
aras&#305;ndad&#305;r. Olgular&#305;n ï¿½ok daha bï¿½yï¿½k bir k&#305;sm&#305;nda ise
sadece kortikal ve subkortikal atrofi gï¿½rï¿½lï¿½r. Radyoterapi ile birlikte metotreksat
da verilmi&#351;se lï¿½koensefalopati geli&#351;me riski artar. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>B.
Radyasyon Miyelopatisi: </span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>(Ayr&#305;ca bak&#305;n&#305;z: <u><span
style='color:#0070C0'><a href="../omurilik/omurilik.htm">Omurilik
Hastal&#305;klar&#305;</a></span></u>) </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>1. <i>Akut
miyelopati</i>: Spinal radyoterapi sonras&#305;nda akut miyelopati gï¿½rï¿½lï¿½p
gï¿½rï¿½lmeyece&#287;i tart&#305;&#351;mal&#305; bir konudur. Tedavinin ilk
gï¿½nlerinde ortaya ï¿½&#305;kabilece&#287;i gibi haftalar iï¿½erisinde de
olu&#351;abilir. Genelde, boyun bï¿½lgesinin
&#305;&#351;&#305;nlanmas&#305;n&#305; izleyerek ortaya ï¿½&#305;kan <i>Lhermitte
belirtisi</i> ile tan&#305;n&#305;r. Medulla spinalisdeki fokal demiyelizasyona
ba&#287;l&#305; olarak hasta ba&#351;&#305;n&#305; fleksiyona getirdi&#287;inde
gï¿½vde ve bacaklara, bazen de kollara yay&#305;lan, anl&#305;k bir elektriklenme
hissinden yak&#305;n&#305;r. Haftalar iï¿½erisinde spontan olarak dï¿½zelen bu
tablo iï¿½in tedavi gerekli de&#287;ildir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>2. <i>Erken
gecikmi&#351; miyelopati</i>: Radyoterapiden sonraki 3-5 ay iï¿½inde ortaya
ï¿½&#305;kan paresteziler ve <i>Lhermitte</i> bulgusu ile karakterizedir. Bu
tablodan arka kordonlarda ortaya ï¿½&#305;kan demiyelinizasyonun sorumlu
oldu&#287;u dï¿½&#351;ï¿½nï¿½lmektedir. Genellikle de birkaï¿½ ay iï¿½inde
kendili&#287;inden dï¿½zelir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>3. <i>Geï¿½
gecikmi&#351; miyelopati</i>: Geï¿½ radyasyon miyelopatisi ba&#351;l&#305;ca ï¿½ï¿½ &#351;ekilde
gï¿½rï¿½lï¿½r. En s&#305;k gï¿½rï¿½leni 1-4 y&#305;l iï¿½inde ba&#351;lay&#305;p
h&#305;zl&#305; veya yava&#351; bir progresyonla paraparezi veya tetraparezi
ile sonlan&#305;r. Klinik tablo; a&#287;r&#305;s&#305;z ve ï¿½ncelikle medulla
spinalisin daha ï¿½ok radyasyon alan yar&#305;s&#305; etkilenmi&#351;
oldu&#287;undan tam ya da parsiyel bir <i>Brown-Sequard sendromu</i> olarak
kar&#351;&#305;m&#305;za ï¿½&#305;kar. Benzer bir klinik tabloya yol aï¿½abilecek
epidural bas&#305; gibi olas&#305;l&#305;klar&#305;n d&#305;&#351;lanmas&#305;
iï¿½in MRG yap&#305;lmal&#305;d&#305;r. MRG bas&#305;y&#305; d&#305;&#351;lar;
genellikle normaldir, ancak omurilikte kontrast tutan hafif &#351;i&#351; bir
bï¿½lge gï¿½rï¿½lebilir. Radyoterapi bï¿½lgesi hakk&#305;nda ayr&#305;nt&#305;l&#305;
bilgi yoksa, &#305;&#351;&#305;nlanan bï¿½lgedeki vertebra
korpuslar&#305;n&#305;n ya&#287;l&#305; doku nedeniyle hiperintens gï¿½rï¿½nmesi
&#305;&#351;&#305;nlanan bï¿½lgenin s&#305;n&#305;rlar&#305; hakk&#305;nda ipucu
verir. Omurilik parenkim hasar&#305; d&#305;&#351;&#305;nda pelvik
&#305;&#351;&#305;nlamay&#305; izleyerek alt ekstremitelerde ortaya ï¿½&#305;kan
motor nï¿½ron sendromu ve intraspinal kanamalar da spinal radyoterapinin geï¿½
komplikasyonlar&#305; olarak kar&#351;&#305;m&#305;za ï¿½&#305;kabilir. Bu iki
durum da radyoterapiden uzun y&#305;llar sonra gï¿½rï¿½lebilir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>C.
Radyasyona Ba&#287;l&#305; Kranyal ve Periferik Nï¿½ropatiler</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Radyasyona
ba&#287;l&#305; kranyal ve periferik nï¿½ropatiler nadiren de olsa gï¿½rï¿½lebilir.
Optik nï¿½ropati radyoterapiden 6 ay-2 y&#305;l sonra geli&#351;en
a&#287;r&#305;s&#305;z tek veya iki yanl&#305; kï¿½rlï¿½k ile ortaya ï¿½&#305;kar.
Papilï¿½dem gï¿½rï¿½lebilir. MRGï¿½de optik sinirde kontrast tutulumu olabilir. Benzer
&#351;ekilde di&#287;er kranyal sinirlerde de radyasyon hasar&#305; nadiren
bildirilmi&#351;tir. Bunlar&#305;n d&#305;&#351;&#305;nda radyasyon
pleksopatileri gï¿½rï¿½lebilir. Genellikle radyoterapiden bir y&#305;l&#305;
a&#351;k&#305;n sï¿½re sonra geï¿½-gecikmi&#351; tablolar ortaya ï¿½&#305;kar.
A&#287;r&#305;s&#305;z zaaf ve duyu kusuru olur. Radyasyon pleksopatisini
olas&#305; bir tï¿½mï¿½r infiltrasyonundan ay&#305;rmak ï¿½nemlidir. Tï¿½mï¿½r
infiltrasyonu genellikle a&#287;r&#305;l&#305;d&#305;r. Ayr&#305;ca, i&#287;ne
EMGï¿½sinde tutulan kaslarda miyokimi varl&#305;&#287;&#305; radyasyon
pleksopatisi iï¿½in oldukï¿½a tan&#305; koydurucu say&#305;l&#305;r
(Bak&#305;n&#305;z: <u><span style='color:#0070C0'><a
href="../spinalsinir/spinalsinir.html">Spinal Sinirlerin Hastal&#305;klar&#305;</a></span></u>).
</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>D.
Radyasyonun &#304;ndirekt Etkileri</span></i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Burada sï¿½zï¿½
edilmesi gereken ba&#351;l&#305;ca konular kranyal &#305;&#351;&#305;nlamadan
y&#305;llar sonra ortaya ï¿½&#305;kan <i>ikincil tï¿½mï¿½rler</i>, <i>bï¿½yï¿½k damar
hastal&#305;&#287;&#305;</i> ve <i>hipotalamo-hipofizer yetmezlik</i>
tablolar&#305;d&#305;r. ï¿½ocukluk ï¿½a&#287;&#305;nda kranyal
&#305;&#351;&#305;nlama yap&#305;lm&#305;&#351; hastalarda ileride meningiom,
gliom, Schwannom gibi tï¿½mï¿½rlerin geli&#351;me riski anlaml&#305; olarak daha
yï¿½ksektir. Ortalama latans ise yakla&#351;&#305;k 17 y&#305;ld&#305;r. Benzer
&#351;ekilde radyoterapiden y&#305;llar sonra damarsal komplikasyonlar
geli&#351;ebilir. Radyoterapi her boyda damar ï¿½zerinde olumsuz etki gï¿½sterir.
Kï¿½ï¿½ï¿½k damarlarda t&#305;kanma yukar&#305;da sï¿½z edilen radyonekroza yol aï¿½ar.
Bunun d&#305;&#351;&#305;nda &#305;&#351;&#305;nlama penceresi iï¿½inde kalan
bï¿½yï¿½k serebral damarlarda da h&#305;zlanm&#305;&#351; ateroskleroz gï¿½rï¿½lï¿½r;
ancak ortaya ï¿½&#305;kan darl&#305;klar&#305;n yerle&#351;imi atipiktir. Bu
durum radyoterapiden aylar veya y&#305;llar sonra belirti verebilir. Burada
yakla&#351;&#305;m klasik aterosklerotik hastal&#305;ktan farks&#305;zd&#305;r.
</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Sinir Sisteminin Paraneoplastik Sendromlar&#305;</span></b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span><span
lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Genel
ï¿½zellikler</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tï¿½mï¿½rlerin
metastaz, direkt yay&#305;l&#305;m, metabolik ve vaskï¿½ler etkilerinin
d&#305;&#351;&#305;nda sinir sistemi ï¿½zerindeki uzak etkileri paraneoplastik
sendromlar olarak tan&#305;mlan&#305;r. Nï¿½rolojinin oldukï¿½a nadir
kar&#351;&#305;la&#351;&#305;lan hastal&#305;klar&#305; olmalar&#305;na
kar&#351;&#305;n, sistemik bir kanserin erken habercisi olmalar&#305; nedeniyle
ï¿½nem ta&#351;&#305;rlar. Paraneoplastik sendromlar&#305;n en belirgin
ï¿½zelli&#287;i, genellikle tï¿½mï¿½r tan&#305;s&#305;ndan ï¿½nce belirti vermesidir.
Bu nedenle hasta ï¿½o&#287;u zaman ï¿½nce nï¿½roloji ile u&#287;ra&#351;an hekimin
kar&#351;&#305;s&#305;na gelir ve tan&#305;y&#305; burada almas&#305; gerekir.
&#304;kincisi, paraneoplastik sendromlar&#305;n alt&#305;nda yatan tï¿½mï¿½rlerin
genellikle benzerlerine oranla daha s&#305;n&#305;rl&#305; ve sinsi seyirli
olmas&#305;, bu nedenle tedavi edilebilir olmas&#305;d&#305;r. Paraneoplastik
sendrom belirtileri ortaya ï¿½&#305;kt&#305;&#287;&#305;nda tï¿½mï¿½r genellikle
bï¿½lgesel lenf nodlar&#305; d&#305;&#351;&#305;nda non-metastatiktir. Buna
kar&#351;&#305;n nï¿½rolojik tablo s&#305;kl&#305;kla a&#287;&#305;rd&#305;r ve
ciddi ï¿½zï¿½rlï¿½lï¿½k yarat&#305;r; ï¿½o&#287;u zaman da geri dï¿½nï¿½&#351;sï¿½zdï¿½r.
Nï¿½rolojik tablo genellikle subakut ba&#351;lar, haftalar-aylar iï¿½inde ilerler,
belirli bir dï¿½zeye ula&#351;&#305;nca da orada stabilize olur. Bu nedenle
nï¿½rolojik tablonun erken tan&#305;nmas&#305; da, tï¿½mï¿½rï¿½n ilerlemeden tedavi
edilme &#351;ans&#305;n&#305; verir. Bu tablolar&#305;n bir di&#287;er ï¿½nemli
ï¿½zelli&#287;i de, a&#351;a&#287;&#305;da daha ayr&#305;nt&#305;l&#305;
anlat&#305;laca&#287;&#305; gibi, paraneoplastik sendrom tipinin aranacak
kanserin tipi hakk&#305;nda ipucu vermesi ve bï¿½ylece kanserin
aranaca&#287;&#305; bï¿½lgeye hekimi yï¿½neltmesidir (<b>Tablo 6</b>). Orta
ya&#351;&#305;n ï¿½zerindeki hastalarda, subakut olarak geli&#351;en duysal
polinï¿½ropati, serebellar sendrom, dermatomiyozit ve Lambert-Eaton sendromu
tan&#305;lar&#305;n&#305;n alt&#305;nda mutlak sistemik bir malignitenin
varl&#305;&#287;&#305; ara&#351;t&#305;r&#305;lmal&#305;d&#305;r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>Tablo 6. Sinir sisteminin paraneoplastik sendromlar&#305;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width=614 style='width:460.5pt;
 mso-cellspacing:1.5pt;background:#FFFFCC;border:outset gray 1.0pt;mso-padding-alt:
 0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width="50%" valign=top style='width:50.0%;border:inset gray 1.0pt;
  background:#FF6666;padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>Merkezi sinir sistemi</span></p>
  </td>
  <td width="50%" valign=top style='width:50.0%;border:inset gray 1.0pt;
  background:#FF6666;padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal><span lang=TR style='font-size:13.5pt;font-family:Tahoma;
  mso-ansi-language:TR'>Periferik sinir / kas</span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes'>
  <td width="50%" valign=top style='width:50.0%;border:inset gray 1.0pt;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>ï¿½Klasikï¿½ paraneoplastik sendromlar</span></b><span lang=DE
  style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l5 level1 lfo16;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Subakut
       serebellar dejenerasyon </span><span lang=DE style='mso-ansi-language:
       DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l5 level1 lfo16;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       ensefalomiyelit (PEM) (<u>+</u>SSN) </span><span lang=DE
       style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l5 level1 lfo16;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Opsoklonus-miyoklonus-ataksi
       </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l5 level1 lfo16;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>ï¿½Stiff-personï¿½
       sendromu </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l5 level1 lfo16;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Limbik ensefalit
       </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
  </ul>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Klasik olmayan paraneoplastik sendromlar</span></b><span lang=DE
  style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l12 level1 lfo19;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       beyinsap&#305; ensefaliti </span><span lang=DE style='mso-ansi-language:
       DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l12 level1 lfo19;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nekrotizan
       miyelopati </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l12 level1 lfo19;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       motor nï¿½ron hastal&#305;&#287;&#305; </span><span lang=DE
       style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l12 level1 lfo19;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
       retinopati/ optik nï¿½ropati </span></li>
  </ul>
  </td>
  <td width="50%" valign=top style='width:50.0%;border:inset gray 1.0pt;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>ï¿½Klasikï¿½ paraneoplastik sendromlar</span></b></p>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l9 level1 lfo22;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Subakut duysal
       nï¿½ronopati (SSN) (<u>+</u>PEM)&nbsp; </span><span lang=FR
       style='mso-ansi-language:FR'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l9 level1 lfo22;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Subakut
       sensori-motor nï¿½ropati </span></li>
   <li class=MsoNormal style='mso-list:l9 level1 lfo22;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Lambert-Eaton
       miyastenik sendromu </span></li>
   <li class=MsoNormal style='mso-list:l9 level1 lfo22;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nï¿½romiyotoni </span></li>
   <li class=MsoNormal style='mso-list:l9 level1 lfo22;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Dermatomiyozit </span><span
       lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
  </ul>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></b><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span></b><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Klasik olmayan paraneoplastik sendromlar</span></b><span lang=DE
  style='mso-ansi-language:DE'><o:p></o:p></span></p>
  <ul style='margin-top:0cm' type=disc>
   <li class=MsoNormal style='mso-list:l11 level1 lfo25;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Polimiyozit </span><span
       lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l11 level1 lfo25;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>AIDP / CIDP </span><span
       lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l11 level1 lfo25;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Vaskï¿½litik
       nï¿½ropati </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l11 level1 lfo25;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Miyastenia
       gravis </span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></li>
   <li class=MsoNormal style='mso-list:l11 level1 lfo25;tab-stops:list 36.0pt'><span
       lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nekrotizan
       miyopati </span></li>
  </ul>
  </td>
 </tr>
</table>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
sendromlar kad&#305;nlarda erkeklere oranla daha s&#305;k gï¿½rï¿½lï¿½r. Tam olarak insidensi
bilinmemekle beraber, klinik olarak belirti veren paraneoplastik sendrom,
kanserli hastalar&#305;n % 5ï¿½inden az&#305;nda gï¿½rï¿½lï¿½r. S&#305;k
kar&#351;&#305;la&#351;&#305;lan maligniteler kï¿½ï¿½ï¿½k hï¿½creli akci&#287;er
kanseri (olgular&#305;n %3ï¿½ï¿½nde paraneoplastik sendrom geli&#351;ir), timoma
(olgular&#305;n %15ï¿½inde paraneoplastik sendrom geli&#351;ir) ve monoklonal
gamopatiler ile ili&#351;kili hematolojik malignitelerdir (olgular&#305;n
%5-15ï¿½inde paraneoplastik sendrom geli&#351;ir). Kï¿½ï¿½ï¿½k hï¿½creli akci&#287;er
kanseri d&#305;&#351;&#305; solid tï¿½mï¿½rlerde paraneoplastik sendrom gï¿½rï¿½lme
s&#305;kl&#305;&#287;&#305; %1ï¿½in alt&#305;ndad&#305;r. Subklinik
olgular&#305;n % 50ï¿½lere ula&#351;abilece&#287;ini ï¿½ne sï¿½ren yazarlar varsa da
bu konu netlik kazanmam&#305;&#351;t&#305;r. Paraneoplastik sendrom
semptomlar&#305;, olgular&#305;n %60ï¿½&#305;nda kanser tan&#305;s&#305;ndan ï¿½nce
ortaya ï¿½&#305;karken, %40ï¿½&#305;nda tï¿½mï¿½r tan&#305;s&#305;ndan sonra veya nï¿½ks
s&#305;ras&#305;nda ortaya ï¿½&#305;kar. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
sendromlar&#305;n tan&#305;s&#305; nï¿½rolojik sendromun tan&#305;nmas&#305;,
ili&#351;kili kanserin gï¿½sterilmesi ve serum/BOS antikorlar&#305;n&#305;n
saptanmas&#305; ile konur. Merkezi sinir sistemini ilgilendiren paraneoplastik
sendromlarda nï¿½roradyolojik incelemeler, baz&#305; istisnalar
d&#305;&#351;&#305;nda s&#305;kl&#305;kla negatif kal&#305;r; ï¿½o&#287;u zaman
parenkim atrofisi d&#305;&#351;&#305;nda bulgu vermez. Lezyon saptanabilen
olgularda ise kan-beyin bariyeri korunmu&#351; oldu&#287;undan genellikle
kontrast tutan lezyon bulma olas&#305;l&#305;&#287;&#305; dï¿½&#351;ï¿½ktï¿½r. Ancak
baz&#305; istisnalar da vard&#305;r. Paraneoplastik limbik ensefalit
olgular&#305;nda limbik sistem yap&#305;lar&#305; MRï¿½da hiperintens
gï¿½rï¿½nebilir. MR incelemesinin negatif oldu&#287;u paraneoplastik ensefalit
olgular&#305;nda FDG-PET incelemesinin merkezi sinir sistemi
lezyonlar&#305;n&#305; gï¿½sterebildi&#287;i bildirilmi&#351;tir. Ensefalit
olgular&#305;nda gï¿½rï¿½lebilen non-konvï¿½lzif epileptik status tablosu EEG
incelemesi ile saptanabilir. Periferik sinir sistemini ve kas&#305;
ilgilendiren paraneoplastik sendromlarda EMG tan&#305;ya yard&#305;mc&#305;d&#305;r.
BOS normal olabilirse de s&#305;kl&#305;kla inflamatuvar ï¿½zellikler gï¿½sterir.
Il&#305;ml&#305; veya orta dï¿½zeyde pleositoz, protein art&#305;&#351;&#305;,
&#304;gG art&#305;&#351;&#305; ve oligoklonal bantlar gï¿½rï¿½lebilir.
Paraneoplastik sendroma benzer tablolar&#305;n kanser d&#305;&#351;&#305; pek
ï¿½ok sebeple de ortaya ï¿½&#305;kabildi&#287;i unutulmamal&#305;d&#305;r. Kanser
metastaz&#305;, f&#305;rsatï¿½&#305; infeksiyonlar ve kemoterapi/radyoterapi yan
etkileri bunlardan baz&#305;lar&#305;d&#305;r. Karsinomatï¿½z menenjiti
d&#305;&#351;lamak iï¿½in de lomber ponksiyon yap&#305;lmas&#305; gereklidir.
Kanseri bulunmayan baz&#305; hastalarda benzer tablolar&#305;n otoimmun
hastal&#305;klar&#305;n seyri s&#305;ras&#305;nda da gï¿½rï¿½lebilece&#287;i
unutulmamal&#305;d&#305;r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
sendromlar genelikle kanserin erken evrelerinde geli&#351;ir ve bu yï¿½zden
tï¿½mï¿½rï¿½n gï¿½sterilmesi mï¿½mkï¿½n olmayabilir. Altta yatan tï¿½mï¿½r, ï¿½o&#287;u zaman,
gï¿½&#287;ï¿½s, abdomen ve pelvis BTï¿½si ile gï¿½sterilebilir. Sendromun veya
paraneoplastik antikorun bilinmesi, gï¿½rï¿½ntï¿½lenmesi hedeflenen bï¿½lgenin daha iyi
seï¿½ilmesini sa&#287;lar (anti-Yo pozitif olguda mamografi, anti-Ma pozitif
olguda testis ultrasonografisi gibi). FDG-PET incelemesi kï¿½ï¿½ï¿½k primer
tï¿½mï¿½rlerin ve metastazlar&#305;n gï¿½sterilmesini ve biyopsi iï¿½in olas&#305;
bï¿½lgelerin belirlenmesini sa&#287;lar.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Patogenez</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
sendromlar&#305;n neden ve nas&#305;l ortaya ï¿½&#305;kt&#305;klar&#305; tam
olarak bilinmemekle beraber, geï¿½mi&#351; y&#305;llardan bu yana patogenezde
baz&#305; teoriler ileri sï¿½rï¿½lmektedir. Bugï¿½n en yayg&#305;n kabul gï¿½ren teori
otoimmï¿½n teoridir. Otoimmï¿½n hastal&#305;&#287;a, ya f&#305;rsatï¿½&#305;
infeksiyona ba&#287;l&#305; molekï¿½ler taklit, ya da tï¿½mï¿½rde baz&#305;
onko-nï¿½ral antijenlerin ekspresyonunun yol aï¿½t&#305;&#287;&#305;
dï¿½&#351;ï¿½nï¿½lmektedir. Ancak, paraneoplastik sendromun s&#305;kl&#305;kla erken
dï¿½nemde kanser henï¿½z s&#305;n&#305;rl&#305; iken geli&#351;ti&#287;i, yani
tï¿½mï¿½re ba&#287;l&#305; immunsupresyonun geli&#351;mesinden ï¿½nce ortaya
ï¿½&#305;kt&#305;&#287;&#305; dï¿½&#351;ï¿½nï¿½lï¿½rse, f&#305;rsatï¿½&#305; enfeksiyonlar&#305;n
pek sï¿½z konusu olamayaca&#287;&#305; gï¿½rï¿½lmektedir. Bu durumda ikinci
olas&#305;l&#305;k daha akla yak&#305;n gï¿½rï¿½nmektedir. Onko-nï¿½ral antijenler
fetal ya&#351;am sonras&#305; periferik dokularda kaybolan ve MSS iï¿½ine
sekestre olan antijenlerdir. MSSï¿½nin ba&#287;&#305;&#351;&#305;kl&#305;k
sisteminden korunmu&#351; yap&#305;s&#305; iï¿½inde yer alan bu ilkel antijenler,
baz&#305; tï¿½mï¿½rler taraf&#305;ndan da sergilenir ve tï¿½mï¿½re yï¿½nelen
ba&#287;&#305;&#351;&#305;kl&#305;k sistemi ï¿½gelerinin hedefi haline gelir. Bu
antijenlerin ï¿½ncelikle CD4-haf&#305;za T-lenfositlerini aktive etti&#287;i
dï¿½&#351;ï¿½nï¿½lmektedir. Ayn&#305; zamanda, B-lenfositler aktive olur ve otoantikor
ï¿½retimi ba&#351;lar. Bu otoantikorlar&#305;n patogenezdeki gerï¿½ek rolï¿½ tam
olarak bilinmemektedir. MSS hasar&#305;n&#305;n sitotoksik T-lenfosit
yan&#305;t&#305; sonucunda gerï¿½ekle&#351;ti&#287;i dï¿½&#351;ï¿½nï¿½lmektedir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Paraneoplastik Sendromlarda Otoantikorlar (Tablo 7 ve 8):</span></i></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Paraneoplastik oldu&#287;u bilinen pek ï¿½ok hastal&#305;kta &#304;gG
yap&#305;s&#305;nda otoantikorlar saptanmaktad&#305;r. Bu otoantikorlar
tan&#305;d&#305;klar&#305; antijene gï¿½re isimlendirilse de (anti-amfifizin
gibi), ilk tan&#305;mlanan otoantikorlar s&#305;ras&#305;nda kullan&#305;lan
bir yï¿½ntemle antikorun ilk kez gï¿½sterildi&#287;i hastan&#305;n ad&#305;n&#305;n
ilk iki harfi ile de adland&#305;r&#305;l&#305;rlar (ani-Hu, anti-Yo, anti-Ri,
gibi). Baz&#305; tï¿½mï¿½rlere ve baz&#305; paraneoplastik sendromlara ï¿½zgï¿½
otoantikorlar vard&#305;r. Her otoantikor sinir sisteminin belirli hï¿½crelerinin
belirli bï¿½lï¿½mleri ile ve bir de tï¿½mï¿½rle immunhistokimyasal reaksiyon verir;
genellikle hastan&#305;n ba&#351;ka dokular&#305;yla veya ba&#351;ka
hastalardan elde edilen benzer tipteki tï¿½mï¿½r dokusu ile reaksiyon vermez.
Hastalar&#305;n serum veya BOS ï¿½rneklerinde anti-nï¿½ronal antikorlar&#305;n
gï¿½sterilmesi tan&#305;y&#305; kolayla&#351;t&#305;rmakla beraber olgular&#305;n
%40ï¿½&#305;nda antikor gï¿½sterilemez. Bu antikorlar sa&#287;l&#305;kl&#305;
ki&#351;ilerde bulunmaz, paraneoplastik sendrom yaratmayan benzer kanserlerde
ya bulunmaz, ya da ï¿½ok dï¿½&#351;ï¿½k titrededirler. Genellikle BOSï¿½taki antikor
dï¿½zeyi serumdakinden ï¿½ok daha yï¿½ksektir; bu intratekal antikor sentezinin de
bulundu&#287;unu gï¿½sterir. Bu antikorlar&#305;n paraneoplastik hastal&#305;k
olu&#351;umunda oynad&#305;klar&#305; rol tam bilinmemektedir. Hedef
antijenlerin hï¿½cre yï¿½zeyindeki reseptï¿½rler oldu&#287;u Lambert-Eaton miyastenik
sendromu ve miyastenia gravis gibi ï¿½ok az say&#305;da tabloda ve ayr&#305;ca
anti-amfifizinle ili&#351;kili ï¿½stiff-personï¿½ sendromunda paraneoplastik
antikorlar&#305;n hastal&#305;&#287;a yol aï¿½t&#305;&#287;&#305;
kan&#305;tlanm&#305;&#351;t&#305;r. Di&#287;er paraneoplastik
hastal&#305;klarda (ï¿½zellikle intraselï¿½ler antijenlere kar&#351;&#305;
antikorlarla ili&#351;kili hastal&#305;klarda) anti-nï¿½ronal antikorlar&#305;n
pasif nakli veya antijenlerle yap&#305;lan aktif immunizasyonla bugï¿½ne dek
hayvan modellerinde hastal&#305;k olu&#351;turulamam&#305;&#351;t&#305;r. Hï¿½cre
membran&#305; antijenlerine (ï¿½rne&#287;in voltaja duyarl&#305; potasyum
kanal&#305; ve N-metil D-aspartat tipi glutamat reseptï¿½rï¿½ ile ili&#351;kili
limbik ensefalit) kar&#351;&#305; antikorlarla ili&#351;kili paraneoplastik
sendromlarda serum ve BOS antikor titreleri ile klinik bulgular&#305;n
a&#287;&#305;rl&#305;&#287;&#305; aras&#305;nda ili&#351;ki bulunmaktad&#305;r.
Ancak hï¿½cre iï¿½i antijenlerle (ï¿½rne&#287;in Hu, Yo, Ma) ili&#351;kili
sendromlarda tedaviyle serum veya BOSï¿½ta antikor titresi dï¿½&#351;se de klinik
bulgularda dï¿½zelme olmaz. Bugï¿½n bu antikorlar daha ï¿½ok tan&#305;da yol
gï¿½sterici olmaktad&#305;r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p style='margin:0cm;margin-bottom:.0001pt'><b><span lang=TR style='font-size:
13.5pt;font-family:Tahoma;color:black;mso-ansi-language:TR'>Tablo 7.
Paraneoplastik sendromlarda otoantikorlar</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> </span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p style='margin:0cm;margin-bottom:.0001pt'><span lang=TR style='mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span
style='mso-spacerun:yes'>ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½
</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:480;mso-padding-alt:0cm 5.4pt 0cm 5.4pt;mso-border-insideh:
 .5pt solid windowtext;mso-border-insidev:.5pt solid windowtext'>
 <tr style='mso-yfti-irow:0'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:
  TR'>Antikor&nbsp;&nbsp;</span></b><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kanser&nbsp;&nbsp;</span></b><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:13.5pt;font-family:Tahoma;mso-ansi-language:
  TR'>Sendrom</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-Hu&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>KHAK&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>PEM / SSN<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-Yo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Meme,
  jinekolojik<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>SCD <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-Ri&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Meme,
  jinekolojik&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>POMA<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-amfifizin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Meme&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>ï¿½Stiff-personï¿½,
  limbik ensefalit<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-VGCC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>KHAK&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>LEMS, SCD<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-Ma&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>ï¿½e&#351;itli<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Beyinsap&#305;
  ensefaliti, SCD<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-Ma2
  (Ta)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Testis&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Limbik
  ensefalit, beyinsap&#305; ensefaliti<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-Tr&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Hodgkin
  hastal&#305;&#287;&#305; &nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>SCD<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-CAR&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>KHAK<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Retinopati<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-CV2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>KHAK&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>PEM / SCD
  /SSN<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;mso-yfti-lastrow:yes'>
  <td width=206 valign=top style='width:154.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>anti-NMDAR&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Over
  teratomu&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=206 valign=top style='width:154.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Limbik
  ensefalit<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>K&#305;saltmalar iï¿½in metne bak&#305;n&#305;z</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;color:black;mso-ansi-language:
TR'>Tablo 8. Paraneoplastik sendromlarda altta yatan tï¿½mï¿½re gï¿½re otoantikorlar.</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p style='margin:0cm;margin-bottom:.0001pt'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sendrom&nbsp;&nbsp;&nbsp;&nbsp;<span
style='mso-spacerun:yes'>ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ </span>Tï¿½mï¿½r</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:480;mso-padding-alt:0cm 5.4pt 0cm 5.4pt;mso-border-insideh:
 .5pt solid windowtext;mso-border-insidev:.5pt solid windowtext'>
 <tr style='mso-yfti-irow:0'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>KHAK<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>KHAK-d&#305;&#351;&#305;<b>&nbsp;&nbsp;&nbsp;&nbsp;</b><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Meme/Over&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Lenfoma<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>SCD<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>ANNA1&nbsp;<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(anti-Hu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>APCA<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(anti-Yo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>anti-Tr<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>SSN&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>ANNA1&nbsp;<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(anti-Hu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(ï¿½)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>PEM<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>ANNA1&nbsp;<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(anti-Hu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>APCA<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(anti-Yo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;POMA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>ANNA2&nbsp;<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>(anti-Ri)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Stiff-person&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(ï¿½)<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>Anti-amfifizin<o:p></o:p></span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>(++)&nbsp;<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=TR style='mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>K&#305;saltmalar iï¿½in metne bak&#305;n&#305;z<o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tedavi</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
sendromlar&#305;n tedavisinde en ï¿½nemli yakla&#351;&#305;m altta yatan kanserin
tan&#305;s&#305; ve tedavisidir. Bu durumda nï¿½rolojik tablo tamamen dï¿½zelmese
de en az&#305;ndan stabilize olabilir. Bunun d&#305;&#351;&#305;nda steroidler,
intravenï¿½z immunglobulin (IVIg), plazmaferez gibi immunsupresif veya
immunmodï¿½latï¿½r tedaviler kullan&#305;labilir. Ancak oldukï¿½a pahal&#305; olan bu
tedavilerle de ï¿½o&#287;u zaman yï¿½z gï¿½ldï¿½rï¿½cï¿½ sonuï¿½lar al&#305;nmamaktad&#305;r.
Bununla beraber son y&#305;llarda voltaja duyarl&#305; potasyum kanal&#305; ve
N-metil D-aspartat tipi glutamat reseptï¿½rï¿½ antikorlar&#305; ile ili&#351;kili
limbik ensefalit ve voltaja duyarl&#305; kalsiyum kanal&#305; antikoru ile
ili&#351;kili Lambert-Eaton miyastenik sendromu ve serebellar dejenerasyon
olgular&#305;nda steroid, IVIg ve plazmaferez gibi yï¿½ntemlerle yï¿½ksek tedavi
ba&#351;ar&#305;s&#305; elde edilebilece&#287;i gï¿½sterilmi&#351;tir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;l&#305;ca
Paraneoplastik Sendromlar </span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Baz&#305;
nï¿½rolojik tablolar vard&#305;r ki, bunlar gï¿½rï¿½ldï¿½&#287;ï¿½nde mutlaka
paraneoplastik sendrom akla gelmeli ve altta yatan bir tï¿½mï¿½r
ara&#351;t&#305;r&#305;lmal&#305;d&#305;r. ï¿½Klasikï¿½ paraneoplastik sendromlar
olarak da adland&#305;r&#305;labilecek bu tablolar aras&#305;nda subakut
serebellar dejenerasyon, opsoklonus-miyoklonus-ataksi sendromu, subakut duysal
nï¿½ropati, Lambert-Eaton miyastenik sendromu gibi tablolar yer al&#305;r. 2004
y&#305;l&#305;nda uluslar aras&#305; bir konsorsiyum taraf&#305;ndan belirlenen
kriterlere gï¿½re kesin paraneoplastik sendrom ad&#305;n&#305; vermek iï¿½in
nï¿½rolojik sendromun, antinï¿½ronal antikorla birlikte bulunmas&#305; ve altta
yatan kanserin mevcut olmas&#305;, nï¿½rolojik tablo ve kanserin ortaya
ï¿½&#305;k&#305;&#351;&#305;n&#305;n ise en fazla 5 y&#305;l ara ile
gerï¿½ekle&#351;mesi gereklidir. Bu ko&#351;ullar&#305;n d&#305;&#351;&#305;nda
kesin paraneoplastik sendrom olarak adland&#305;r&#305;labilmek iï¿½in
a&#351;a&#287;&#305;daki 4 seï¿½enekten birine uymas&#305; gereklidir: 1.
ï¿½Klasikï¿½ nï¿½rolojik sendrom ve kanser (en fazla 5 y&#305;l ara ile); 2. Kansere
e&#351;lik eden ve tï¿½mï¿½rï¿½n tedavisi ile iyile&#351;en klasik olmayan sendrom
(spontan iyile&#351;ebilen bir hastal&#305;k olmamal&#305;); 3. Klasik olmayan
sendromla birlikte kanserin (en fazla 5 y&#305;l ara ile) ve antinï¿½ronal
antikorlar&#305;n saptanmas&#305;; 4. Nï¿½rolojik sendrom klasik olsun veya olmas&#305;n,
kanser saptanamasa bile iyi karakterize edilmi&#351; (klasik)
otoantikorlar&#305;n saptanmas&#305; (Hu, Yo, Ri, vs). Bu kriterleri tam olarak
kar&#351;&#305;lamayan geri kalan bï¿½tï¿½n durumlar&#305;n da olas&#305;
paraneoplastik sendrom olarak adland&#305;r&#305;lmas&#305; ï¿½nerilmi&#351;tir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Subakut
serebellar dejenerasyon (SCD)</span></i></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>: ï¿½Klasikï¿½ paraneoplastik sendromlar&#305;n en
s&#305;k gï¿½rï¿½lenidir. Haftalar-aylar iï¿½inde ilerleyen bu serebellar sendromda;
gï¿½vde ve taraf ataksisi, dizartri, horizontal ve vertikal nistagmus ortaya
ï¿½&#305;kar, bir sï¿½re sonra a&#287;&#305;r sekelle tablo sabitle&#351;ir. Ender
olarak diplopi, i&#351;itme kayb&#305;, yutma zorlu&#287;u, piramidal bulgular
ve polinï¿½ropati e&#351;lik edebilir. Erken BT/MR normaldir; geï¿½ dï¿½nemde
serebellar atrofi, bazen serebellum ak maddesinde hiperintensite gï¿½rï¿½lebilir.
Histopatolojide yo&#287;un ve selektif Purkinje hï¿½cre kayb&#305; sï¿½z konusudur.
Serebellumda erken evrelerde yo&#287;un inflamasyon bulgular&#305; gï¿½rï¿½lï¿½rken,
hastal&#305;&#287;&#305;n ileri evrelerinde inflamatuvar hï¿½creler kaybolur.
SCDï¿½de en s&#305;k anti-Yo antikorlar&#305; (= ï¿½anti-purkinje cellï¿½
antikorï¿½APCA) saptan&#305;r. Hemen daima meme, over veya di&#287;er jinekolojik
kanserlerle ili&#351;kilidir; ancak lenfoma veya akci&#287;er kanserinde de
gï¿½rï¿½lebilir. Anti-Yo antikorlar&#305; immunhistokimyasal olarak sadece Purkinje
hï¿½crelerinin sitoplazmas&#305; ile ve sadece SCDï¿½linin tï¿½mï¿½rï¿½ ile reaksiyon
verir. Bu antikor 34 kD ve 62 kD proteinleri tan&#305;r. Daha seyrek orarak
anti-Hu (kï¿½ï¿½ï¿½k hï¿½creli akci&#287;er kanseri), anti-Zic4 (kï¿½ï¿½ï¿½k hï¿½creli
akci&#287;er kanseri) ve anti-Tr (lenfoma) ile ili&#351;kili SCD gï¿½rï¿½lebilir.
Bu sonuncusu, di&#287;er paraneoplastik sendromlar&#305;n aksine 20-40 ya&#351;
aras&#305; erkeklerde daha s&#305;kt&#305;r ve genellikle SCD lenfoma
tan&#305;s&#305;ndan sonra ortaya ï¿½&#305;kar; remisyon da s&#305;kt&#305;r.
Oysa di&#287;er SCDï¿½ler tedaviye pek cevap vermezler. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
ensefalomiyelit/ subakut duysal nï¿½ropati (PEM/SSN): M</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>SSï¿½nin farkl&#305;
bï¿½lgelerinin, arka kï¿½k, gangliyon ve otonomik liflerin etkilenebildi&#287;i
immunolojik mekanizmalarla olu&#351;an inflamatuvar bir hastal&#305;kt&#305;r.
ï¿½n planda hipokampus (limbik ensefalit), beyin sap&#305; (beyinsap&#305;
ensefaliti), diensefalon, serebellumun Purkinje hï¿½creleri (serebellar
dejenerasyon), dorsal kï¿½k-gangli<span style='color:white'>y</span>onu (duysal
nï¿½ronopati), medulla spinalis (miyelit) ve sempatik ve parasempatik sinir ve
gangliyonlar (otonomik bulgular) tutulur. Hemen daima anti-Hu antikorlar&#305;
(= anti-nï¿½ronal nï¿½kleer antikor tip Iï¿½ANNA1) ile ili&#351;kilidir.
Olgular&#305;n %70ï¿½inden fazlas&#305;nda kï¿½ï¿½ï¿½k hï¿½creli akci&#287;er kanseri
(KHAK) ile birlikte gï¿½rï¿½lï¿½r. Bunun d&#305;&#351;&#305;nda adrenal, prostat,
nï¿½roblastom ve farkl&#305; tï¿½r akci&#287;er kanserleri gibi di&#287;er
kanserlerle de gï¿½rï¿½lebilir. Patolojide klinik olarak tutulan bï¿½lgeye bakmaks&#305;z&#305;n
yayg&#305;n lenfositik infiltrasyon ile birlikte nï¿½ron kayb&#305;; tï¿½mï¿½rde de
benzer infiltrasyon gï¿½rï¿½lï¿½r. Anti-Hu antikorlar&#305; immunhistokimyasal olarak
periferik ve santral bï¿½tï¿½n nï¿½ronlar&#305;n nukleusu ile ve bï¿½tï¿½n KHAKï¿½lerle
reaksiyon verir. Paraneoplastik sendromsuz KHAKï¿½de de ï¿½ok dï¿½&#351;ï¿½k titrede
bulunabilir (%15). Bu antikorlar 35-40 kD proteinleri tan&#305;r. Klinik
olgular&#305;n % 25ï¿½inde unifokal iken (SSN, limbik ensefalopati veya
beyinsap&#305; ensefaliti), %75 olguda multifokaldir (SSN, limbik ensefalopati,
beyinsap&#305; ensefaliti, SCD, motor nï¿½ron-benzeri, otonom nï¿½ropati, gï¿½rme
azalmas&#305;; %3 diffï¿½z PEM gibi ). Anti-Hu d&#305;&#351;&#305;nda anti-CV2
(KHAK, timoma), anti-Ma (testis kanseri), anti-amfifizin (meme, KHAK), voltaja
duyarl&#305; potasyum kanal&#305; (KHAK, timoma) ve N-metil D-aspartat
reseptï¿½rï¿½ (over teratomu) antikorlar&#305; ile ili&#351;kili PEM olgular&#305;
da bildirilmi&#351;tir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
SSN alttan ba&#351;layan parestezi-dizestezi ile ortaya ï¿½&#305;kar,
gï¿½nler/haftalar iï¿½inde ilerler. Semptomlar genellikle asimetriktir, derin
tendon refleksleri s&#305;kl&#305;kla kay&#305;pt&#305;r, derin duyu belirgin
derecede bozulur ve kas gï¿½cï¿½ normaldir. Baz&#305; olgularda derin duyu
kayb&#305; bask&#305;n bulgudur. Bu yï¿½zden duysal ataksi ve ellerde
psï¿½doatetoid hareketler s&#305;kl&#305;kla gï¿½zlenir. Tutulan bï¿½lgeler arka kï¿½k
ve gangliyon oldu&#287;undan BOS incelemesi s&#305;kl&#305;kla patolojik sonuï¿½lar
verir. S&#305;kl&#305;kla anti-Hu ve anti-CV2 antikorlar&#305; ile
ili&#351;kilidir. EMGï¿½de duysal aksonal polinï¿½ropatiyle uyumlu olarak duysal
aksiyon potansiyelleri kaydedilemez, buna kar&#351;&#305;n motor iletiler
normal s&#305;n&#305;rlardad&#305;r. Limbik ensefalopati ise gï¿½nler/haftalar iï¿½inde
ilerleyen davran&#305;&#351;-duygudurum de&#287;i&#351;iklikleri, konfï¿½zyon,
nï¿½betler, halusinasyonlarla ortaya ï¿½&#305;kar. BT/MR normal olabilirse de bazen
meziyal temporal lezyon/kontrast tutulumu gï¿½rï¿½lebilir. Anti-Hu sendromunda
otonom nï¿½ropati ï¿½nemli bir morbidite ve mortalite nedenidir. Tek
ba&#351;&#305;na veya SSN ile birlikte gï¿½rï¿½lï¿½r. Progresif otonom bozukluklarla
karakterizedir. Bazen tï¿½mï¿½r ï¿½&#305;kar&#305;l&#305;nca stabilize olabilirse de
s&#305;kl&#305;kla ï¿½lï¿½m nedeni otonom nï¿½ropati olur. Anti-Hu sendromunda klinik
bulgular genellikle tedaviden yararlanmaz. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Paraneoplastik
opsoklonus-myoklonus-ataksi (POMA): </span></i></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Opsoklonus sakkadik
stabilitenin bozulmas&#305; sonucu ortaya ï¿½&#305;kan istemsiz, aritmik, ï¿½ok
yï¿½nlï¿½, yï¿½ksek amplitï¿½dlï¿½ konjuge sakkadik gï¿½z hareketleri olarak tan&#305;mlanabilir.
POMA sendromunda opsoklonusa s&#305;kl&#305;kla miyokloni, titubasyon ve gï¿½vde
ataksisinin bask&#305;n; taraf ataksisinin geri planda oldu&#287;u serebellar
sendrom e&#351;lik eder. ï¿½ocuklarda olgular&#305;n % 50ï¿½sinde altta yatan
nï¿½roblastoma sï¿½z konusudur ve di&#287;er yandan nï¿½roblastomal&#305;
ï¿½ocuklar&#305;n % 2ï¿½sinde POMA saptan&#305;r. Eri&#351;kinde ise genellikle
non-paraneoplastiktir. Tï¿½mï¿½rle birliktelik % 20-25 olguda sï¿½z konusudur. MR ve
BOS incelemeleri genellikle normaldir. Son y&#305;llarda yap&#305;lan ï¿½al&#305;&#351;malar
tutulan hedef MSS bï¿½lgesinin serebellumun fastigial nukleusu oldu&#287;unu
gï¿½stermi&#351;tir. Bu gruptaki olgular&#305;n ï¿½nemli bir k&#305;sm&#305;nda
antikor gï¿½sterilememektedir. Eri&#351;kinlerde POMA olgular&#305;n&#305;n kï¿½ï¿½ï¿½k
bir k&#305;sm&#305; anti-Ri antikorlar&#305; (= anti-nï¿½ronal nï¿½kleer antikor
tip IIï¿½ANNA2) ile ili&#351;kilidir. Altta yatan kanserler s&#305;kl&#305;kla
meme ve di&#287;er jinekolojik tï¿½mï¿½rlerdir. Daha seyrek olarak kï¿½ï¿½ï¿½k hï¿½creli
akciger kanseri (KHAK), mesane kanseri vs. ile ili&#351;kili olabilir. Anti-Ri
antikorlar&#305; immunhistokimyasal olarak bï¿½tï¿½n santral nï¿½ronlar&#305;n
nukleuslar&#305; ile reaksiyon verir; ANNA1ï¿½in aksine periferik nï¿½ronlarla
reaksiyon vermez. Bu antikor 55 kD ve 80 kD proteinleri tan&#305;r. Bu
sendromla ili&#351;kili antikorlar&#305;n gï¿½nï¿½mï¿½zdeki yï¿½ntemlerle kolayca
gï¿½sterilemeyen, muhtemelen hï¿½cre membran&#305; ve aksonuna ba&#287;lanan
antikorlar oldu&#287;unu destekleyen ï¿½al&#305;&#351;malar vard&#305;r.
POMAï¿½l&#305; hastalarda tï¿½mï¿½r rezeksiyonunun ard&#305;ndan yap&#305;lacak
kortikosteroid, IVIg, plazmaferez gibi tedavi yï¿½ntemleri ile remisyon
gï¿½rï¿½lebilir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kanserle
ili&#351;kili retinopati </span></i></b><b><i><span lang=TR style='font-family:
Symbol;mso-ansi-language:TR'>[</span></i></b><b><i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>ï¿½Cancer associated retinopathyï¿½
(CAR)</span></i></b><b><i><span lang=TR style='font-family:Symbol;mso-ansi-language:
TR'>]</span></i></b><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> Epizodik gï¿½rme azalmalar&#305;, gece kï¿½rlï¿½&#287;ï¿½, &#305;&#351;&#305;k
parlamalar&#305;, fotosensitivite, renkli gï¿½rme azalmas&#305; ile ba&#351;lar,
progresif a&#287;r&#305;s&#305;z gï¿½rme kayb&#305; geli&#351;ir (ï¿½nce tek
yanl&#305;, daha sonra iki yanl&#305; olabilir). Gï¿½z muayenesinde skotomlar,
gï¿½rme keskinli&#287;inde azalma, retinada arterioler daralma, pigment epiteli
birikimi, bazen vitrede hï¿½cre gï¿½rï¿½lebilir. Patolojide fotoreseptï¿½r / gangliyon
hï¿½crelerinin selektif kayb&#305; sï¿½z konusudur. Genellikle KHAK (%60) ve
jinekolojik tï¿½mï¿½rler gibi di&#287;er baz&#305; kanserlerle ili&#351;kili
olabilir. Anti-CAR antikorlar&#305; saptanabilir. Bu antijenler retinal
fotoreseptï¿½r hï¿½crelerde rekoverin (23-48 kD) veya di&#287;er retinal
proteinleri tan&#305;yabilir. Melanoma ile ili&#351;kili retinopatide ise
antikorlar&#305;n hedefi fotoreseptï¿½rler de&#287;il retinan&#305;n bipolar
hï¿½creleridir. &nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>ï¿½Stiff-personï¿½
sendromu:</span></i></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> S&#305;kl&#305;kla (%80) non-paraneoplastiktir. Paraneoplastik formu
anti-amfifizin antikorlar&#305; ile birlikte gï¿½rï¿½lï¿½r ve s&#305;kl&#305;kla meme
kanseri veya KHAK ile ili&#351;kilidir. Progresif rijidite, refleks-spazmlar,
lomber lordoz art&#305;&#351;&#305; ile gider; ba&#351;ka nï¿½rolojik bulgu
olmaz. Bazen aksiyal kaslar yerine taraflarda bask&#305;n olabilir. Patolojik
olarak ï¿½kronik spinal internï¿½ronitisï¿½ sï¿½z konusudur. BOS inflamatuvar
ï¿½zellikler gï¿½sterir. EMGï¿½de sï¿½rekli motor ï¿½nit aktivitesi izlenir. Anti-amfifizin
antikorlar&#305; immunhistokimyasal olarak nï¿½ronlar&#305;n presinaptik
uï¿½lar&#305;yla ve dendritlerle reaksiyon verir ve 128 kD proteini tan&#305;r.
Semptomatik tedavi olarak benzodiazepinler, baklofen yararl&#305; olabilir.
Di&#287;er paraneoplastik sendromlardan farkl&#305; olarak tï¿½mï¿½r rezeksiyonu,
kortikosteroid ve IVIg ile tedavi genellikle mï¿½mkï¿½ndï¿½r.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Lambert
Eaton Miyastenik Sendromu (LEMS):</span></i></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> LEMS hastalar&#305;n&#305;n % 60ï¿½&#305; KHAK
(veya di&#287;er kï¿½ï¿½ï¿½k hï¿½creli kanserlerle) ili&#351;kilidir; % 40ï¿½&#305;nda
ise non-paraneoplastiktir. KHAKï¿½li hastalar&#305;n&#305;n %3ï¿½ï¿½nde LEMS saptanm&#305;&#351;t&#305;r.
Paraneoplastik LEMS erkeklerde daha s&#305;kt&#305;r. Presinaptik bï¿½lgede,
voltaj kap&#305;l&#305; kalsiyum kanallar&#305;na kar&#351;&#305;
antikorlar&#305;n (anti-VGCC) Asetilkolin (Ach) sal&#305;n&#305;m&#305;n&#305;
azaltmas&#305; sonucu hastal&#305;k meydana gelir. Deney hayvanlar&#305;nda
anti-VGCC injeksiyonunun hastal&#305;&#287;&#305; olu&#351;turdu&#287;u
gï¿½sterilmi&#351;tir. Klinik olarak ï¿½abuk yorulma, gï¿½ï¿½sï¿½zlï¿½k ve ï¿½ift gï¿½rme
yak&#305;nmalar&#305; vard&#305;r. S&#305;kl&#305;kla a&#287;&#305;z
kurulu&#287;u, erkeklerde impotans gibi kolinerjik otonom bulgular e&#351;lik
edebilir. Muayenede zay&#305;f bulunan kas gï¿½cï¿½, hastan&#305;n o kas&#305; ï¿½al&#305;&#351;t&#305;rmas&#305;
sonucu fasilite olur ve normale dï¿½ner. Bulber tutulum gï¿½rï¿½lmez; solunum
gï¿½ï¿½lï¿½&#287;ï¿½ olabilir. Refleks kayb&#305; vard&#305;r, ama eforla
pozitifle&#351;ebilir. EMGï¿½de 10-20 Hzï¿½lik repetetif stimï¿½lasyonda ï¿½incrementï¿½
gï¿½rï¿½lmesi veya motor yan&#305;tlar&#305;n kuvvetli ve k&#305;sa sï¿½reli istemli
kas&#305; ile belirgin amplitï¿½d art&#305;&#351;&#305; gï¿½stermesi tan&#305;
koydurucudur. Plazmaferez ve immunsupresyona cevapl&#305; olabilir. Semptomatik
tedavide guanidin, 3-4 DAP (diaminopiridin), antikolinesteraz yararl&#305;
olabilir. Anti-VGCC antikorlar&#305; olan olgularda LEMS tablosuna SCD de
e&#351;lik edebilir ve bu olgularda kï¿½ï¿½ï¿½k hï¿½creli akci&#287;er kanseri ve
anti-Hu bulunma olas&#305;l&#305;&#287;&#305; yï¿½ksektir. Son zamanlarda, SOX
isimli bir nï¿½ronal antijeni tan&#305;yan ve serebellumun Bergman glia hï¿½crelerinin
nukleuslar&#305;na ba&#287;land&#305;&#287;&#305; iï¿½in anti-glial nï¿½kleer
antikor (AGNA) ad&#305; verilen antikorlar&#305;n paraneoplastik LEMS
olgular&#305;n&#305;n yar&#305;s&#305;nda saptand&#305;&#287;&#305; ve bu
yï¿½zden bu antikorlar&#305;n potansiyel bir tan&#305; yï¿½ntemi olarak
kullan&#305;labilece&#287;i bildirilmektedir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Polimiyozit
/ Dermatomiyozit (PM/DM):</span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> Kï¿½ï¿½ï¿½k bir grup olguda paraneoplastiktir.
Ya&#351;l&#305;larda ve dermatomiyozitte kanserle ili&#351;ki ï¿½ok daha
s&#305;kt&#305;r. Meme, akci&#287;er, over, mide, prostat, kolon kanserleri ve
Hodgkin hastal&#305;&#287;&#305; ile ili&#351;kili olabilir. Bilinen bir
otoantikor yoktur. Immun arac&#305;l&#305; bir vaskï¿½lopatidir. Tï¿½mï¿½r tedavisi,
immunsupresif tedavi ve IVIg yararl&#305; olabilir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Subakut
duysal-motor nï¿½ropati:</span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> Seyrek olarak paraneoplastik nedenlidir. Genellikle
akci&#287;er kanseri ile ili&#351;kilidir. H&#305;zl&#305; ilerleyen distal
simetrik polinï¿½ropati, nadiren kronik inflamatuvar demiyelinizan polinï¿½ropati
benzeri seyir gï¿½rï¿½lebilir. EMGï¿½de genellikle aksonal polinï¿½ropati gï¿½rï¿½lï¿½r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Di&#287;er Paraneoplastik Sendromlar</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Anti-Ma ili&#351;kili sendromlar</span></i></b><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>:</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Anti-Ma1 ve Ma2 (Ta) antikorlar&#305; paraneoplastik beyinsap&#305;, limbik sistem
ve diensefalon bulgular&#305; olan olgularda saptanabilirler. Anti-Ma
sendromunda mezensefalon ve diensefalonun ï¿½n planda tutulmas&#305;na
ba&#287;l&#305; olarak zengin okï¿½lomotor bulgular, parkinsonizm, uyku
bozuklu&#287;u ve hiponatremi s&#305;kl&#305;kla gï¿½zlenir. Anti-Ma2 antikoru
daha s&#305;k olarak saptan&#305;r ve olgular&#305;n ï¿½o&#287;u testis kanseri
olan genï¿½ erkeklerdir. Daha nadiren ï¿½zellikle ya&#351;l&#305; erkeklerde ve
kad&#305;nlarda anti-Ma1 ve daha az olarak anti-Ma2 antikoru ile akci&#287;er,
meme, parotis, kolon kanserleri aras&#305;nda ili&#351;ki bildirilmi&#351;tir.
Anti-Ma antikorlar&#305; immunhistokimyasal olarak santral nï¿½ronlar&#305;n ve
testis germ hï¿½crelerinin nukleolusu ile ve sorumlu kanserle reaksiyon verir ve
37-40 kD proteinleri tan&#305;r. Anti-Ma2 (Ta) ile ili&#351;kili testis tï¿½mï¿½rlï¿½
olgularda prognoz di&#287;er paraneoplastik sendromlara gï¿½re daha iyidir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Nekrotizan miyelopati</span></i></b><i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>:</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> lï¿½semi,
lenfoma, akci&#287;er kanseri ile ili&#351;kili olabilir. Asandan parapleji ve
radikï¿½ler a&#287;r&#305; gï¿½rï¿½lï¿½r. MRï¿½da omurilik normal veya &#351;i&#351;
gï¿½rï¿½nebilir, da&#287;&#305;n&#305;k kontrast tutulumu gï¿½sterebilir. Patolojide
omurilikte bï¿½tï¿½n tabakalarda inflamasyonsuz nekroz gï¿½rï¿½lï¿½r. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Miyelit</span></i></b><i><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>:</span></i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Genellikle anti-Hu sendromunun
parï¿½as&#305; olarak kar&#351;&#305;m&#305;za ï¿½&#305;kar. MR normaldir veya
kontrast tutulumu gï¿½steren lezyon gï¿½rï¿½lebilir. Patolojide ï¿½n ve arka boynuzda
bask&#305;n inflamasyon vard&#305;r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p><b><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Paraneoplastik motor nï¿½ron sendromlar&#305;</span></i></b><i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>: </span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lenfoma
ve di&#287;er baz&#305; kanserlerde gï¿½rï¿½lï¿½r; ï¿½ï¿½ grupta incelenebilir:
1.h&#305;zl&#305; ilerleyici motor nï¿½ron hastal&#305;&#287;&#305; + anti-Hu
(KHAK, prostat) ; 2.primer lateral skleroz + antikorsuz (meme); 3.ALS-benzeri +
antikorsuz (meme, jinekolojik, Hodgkin,(KHAK-d&#305;&#351;&#305;). Bu ï¿½ï¿½ï¿½ncï¿½
grupta rastlant&#305;sal olma ihtimali yï¿½ksektir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Kaynaklar</span></i></b><b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>:</span></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>1.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Abrey L, Batchelor T, Fereri A, ve ark. Report of an
international workshop to standardize baseline evaluation and response criteria
for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034-5043.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>2.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Adams RD, Victor M, Ropper AH (editï¿½rler). Principles of
Neurology, 6<sup>th</sup> edition. Mc Graw Hill, New York, 1997. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>3.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Aminoff MJ (editor). Neurology and general medicine (4.
bask&#305;). Churchill Livingstone Elsevier, Philadelphia, 2008.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>4.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Balm M, Hammack J. Leptomeningeal carcinomatosis.
Presenting features and prognostic factors. <i>Arch Neurol</i> 1996; 53: 626. </span><span
lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>5.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Bataller L, Kleopa KA, Wu GF, ve ark. Autoimmune limbic encephalitis
in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry.
2007;78:381.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>6.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Boyaciyan A, Oge AE, Yazici J, Aslay I, Baslo A.
Electrophysiological findings in patients who received radiation therapy over
the brachial plexus: a magnetic stimulation study. Electroencephalogr Clin
Neurophysiol 1996; 101: 483. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:115%'><span
lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:
TR'>7.</span><span lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>Bradley WG,
Daroff RB, Fenichel GM, Jankovic J (editor). Neurology in Clinical Practice
(5th Edition). Butterworth-Heinemann-Elsevier, Philadelphia 2008.</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:115%'><span
lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:
TR'>8.</span><span lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>Brandsma D,
van den Bent MJ. Molecular targeted therapies and chemotherapy in malignant
gliomas. Current Opinion in Oncology 2007; 19: 598-605.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>9.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Dalmau J, Tuzun E, Wu HY, ve ark.. Paraneoplastic
anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian
teratoma. Ann Neurol. 2007;61:25.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>10.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Dalmau JO, Posner JB. Paraneoplastic syndromes. Arch
Neurol 1999; 56: 405. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>11.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Daumas-Duport C, Scheithauer B, Oï¿½Fallon J, Kelly P.
Grading of astrocytomas: a simple and reproducible method. Cancer 1988; 62:
2152. </span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:115%'><span
lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:
TR'>12.</span><span lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:
TR'>&nbsp;&nbsp; </span><span lang=TR style='font-size:10.0pt;line-height:115%;
font-family:Tahoma;mso-ansi-language:TR'>DeVito VT, Hellman S, Rosenberg SA.
Cancer: Principles and Practice of Oncology 7th Edition. Lippincot Williams and
Willkins, Philadelphia 2005.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>13.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Dropcho EJ. Autoimmune central nervous system
paraneoplastic disorders: mechanisms, diagnosis, and therapeutic options. Ann
Neurol 1995; 37 (S1): S102.</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:115%'><span
lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:
TR'>14.</span><span lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:
TR'>&nbsp;&nbsp; </span><span lang=TR style='font-size:10.0pt;line-height:115%;
font-family:Tahoma;mso-ansi-language:TR'>Graus F, Delaterre JY, Antoine JC,
Dalmau J, Giometto B, Grisold W, ve ark. Recommended diagnostic criteria for paraneoplastic
neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-1140.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>15.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Gultekin SH, Rosenfeld MR, Voltz R, ve ark.
Paraneoplastic limbic encephalitis: neurological symptoms, immunological
findings and tumour association in 50 patients. Brain. 2000;123:1481. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>16.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Hardell L, Nasman A, Pahlson A, Hallquist A, Hansson Mild
K. Use of cellular telephones and the risk for brain tumours: A case-control
study. <i>Int J Oncol</i> 1999; 15: 113. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>17.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Hildebrand JG. Prospects in glioma therapy. J Neurol
1999; 246: 3. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>18.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Hoang-Xuan K. Primary central nervous system lymphoma in
immunocompetent patients. J Neurol 1999; 246: 3. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>19.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Jaeckle KA. Autoimmunity in paraneoplastic neurological
syndromes: closer to the truth? Ann Neurol 1999; 45: 143. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>20.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Kadan-Lottick N, Sklusarek M, Gurney J. Decreasing
incidence rates of primary central nervous system lymphoma. Cancer 2002; 95:
193.</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:115%'><span
lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:
TR'>21.</span><span lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:
TR'>&nbsp;&nbsp; </span><span lang=TR style='font-size:10.0pt;line-height:115%;
font-family:Tahoma;mso-ansi-language:TR'>Kan P, Simonsen SE, Lyon JL, Kestle
JR. Cellular phone use and brain tumor: a meta-analysis. J Neurooncol 2008; 86:
71-78.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>22.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Kleihues P, Cavenee W (editï¿½rler). Pathology and
Genetics- Tumours of the Central Nervous System. International Agency for
Research on Cancer, Lyon, 1997. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>23.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Kun LE, Gajjar A, Pollack IF. Pediatric brain tumors.
&#304;ï¿½inde: Perry MC (editï¿½r), American Society of Clinical Oncology 1999
Educational Book. American Society of Clinical Oncology, Alexandria, 1999. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>24.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Mittl RL, Yousem DM. Frequency of unexplained meningeal enhancement
in the brain after lumbar puncture. AJNR Am J Neuroradiol 1994; 15: 633-638.</span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>25.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Patchell RA (editï¿½r). Neurologic Complications of
Systemic Cancer. Neurologic Clinics, Volume 9/4. WB Saunders Company,
Philadelphia, 1991. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>26.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Posner J. Neurologic complications of cancer. FA Davis
Company, Philadelphia, 1995. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>27.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Rosenblum ML (editï¿½r). The Role of Surgery in Brain Tumor
Management. Neurosurgery Clinics of North America. WB Saunders Company,
Philadelphia, 1990. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>28.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>Rowland LP. Merrittï¿½s Textbook of Neurology, 9<sup>th</sup>
edition. Williams and Wilkins, Philadelphia, 1995. </span></p>

<p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:
18.0pt;text-indent:-18.0pt;line-height:115%'><span lang=TR style='font-size:
10.0pt;line-height:115%;font-family:Tahoma;mso-ansi-language:TR'>29.</span><span
lang=TR style='font-size:7.0pt;line-height:115%;mso-ansi-language:TR'>&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'>WasserstromWR, Glass JP, Posner JB. Diagnosis and
treatment of leptomeningial metastases from solid tumors: experience with 90
patients. Cancer 1982; 49 (4): 759-772.</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

</div>

</body>

</html>
